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In 2020, nearly 6.2 million people in Canada aged 15 and older reported using cannabis in the 
last three months (Statistics Canada, 2021). However, some individuals who consume cannabis 
may be more prone than others to experiencing acute (i.e., short-term) adverse reactions to 
cannabis (e.g., paranoia, anxiousness). The primary purpose of this study was to investigate the 
relationship between simultaneous polysubstance use and trait affect on experienced acute 
adverse reactions to cannabis. An exploratory aim was to examine the potential relationship 
between body composition and acute adverse reactions to cannabis. The study was a web-based 
survey, hosted by SurveyMonkey, using a cross-sectional design. Lakehead University students 
and the general public across Canada participated in this study (N = 456). Pearson product-
moment correlations, independent samples t-tests, and hierarchical multiple regression analyses 
were performed to examine the relationships between simultaneous polysubstance use, trait 
affect, body composition, and acute adverse reactions to cannabis. Simultaneous use of cannabis 
and alcohol, trait negative affect, and lower body weight were positively associated with 
experiencing acute adverse reactions to cannabis. The findings from this study have implications 
for people that use cannabis, have high negative affect, prescribing health care providers, and 
public health educators.  
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Simultaneous Polysubstance Use, Trait Affect, Body Composition, and their Associations with 
Acute Adverse Reactions to Cannabis 
Prevalence and Legislation of Cannabis Use 
Worldwide, nearly 147 million people consume cannabis (World Health Organization 
[WHO], 2020). At the end of 2020, approximately 6.2 million Canadians aged 15 and older 
reported using cannabis in the past three months (Statistics Canada, 2021).  ✂✁✂☎✂✟✄☞ annual 
survey for 2019 on Canadian ✏✟✠✡☎☛☞✠✌✠☎☞✄ cannabis use reported that 57.7% of Lakehead 
University students reported using cannabis at least once in the past year (Bronwell, 2019). 
Cannabis is prohibited in most countries worldwide; however, the legality of cannabis use differs 
extensively by country and region. In 2013, Uruguay was the first country to legalize non-
medicinal cannabis use (Cerdá, 2017). Subsequently, Canada was the next country that legalized 
non-medicinal cannabis use in all three domains: possession, consumption, and sale. Medicinal 
cannabis use in Canada has been legal since 2001, when a precedent was set, ruling that the 
prohibition of medicinal ✁✂✟✟✂☎✠☞ ✆✂☞ ✡✠✝✂✂✌✠✟✞ ✂✟ ✠✟✝✠✡✠✝✏✂✂✄☞ ☛✠✞✆✌ ✟✠✁☎✁✠ ☞☎☎ ✡☎✞✠✟✂ v. Parker 
case) to make their own choices about the type of health care they receive (Cox, 2018). The 
Canadian parliament passed the Cannabis Act (i.e., Bill C-45) on June 19th, 2018 (Cannabis Act, 
2018; Crépault, 2018) that legalized selling, purchasing, consuming, and growing cannabis for 
non-medicinal purposes. On October 17th, 2018, Canadians who were a minimum of 18 years of 
age could legally buy, consume, and grow cannabis for non-medicinal purposes (Crépault, 2018). 
The legal minimum age varies across provinces (e.g., British Columbia 19+, Ontario 19+, 
Quebec 18+). Additionally, Canadian adults can possess a maximum of 30 grams of dried 
cannabis or equivalent if cannabis form is non-dried (e.g., one gram of dried cannabis is equal to 
70 grams of liquid product) and grow a maximum of four cannabis plants for non-




commercial/profit for each household (Department of Justice Canada, 2020).  However, edibles 
and concentrates were not legal for sale until the following year, October 17th, 2019 (Department 
of Justice Canada, 2020).  
Cannabis Taxonomy 
Cannabis is the generic name for drugs that come from plants belonging to the species, 
Cannabis sativa L. (e.g., marijuana, weed), which falls under the genus Cannabis (McParland, 
2018; Small & Cronquist, 1976). Cannabis plants can be occasionally monoicous (i.e., 
hermaphroditic), but are mainly dioicous (i.e., male and female) (Thomas & Elsohly, 2016). 
However, it is the female cannabis plants that are typically harvested for their flowering tops 
(i.e., apical/terminal bud) which contain more cannabinoids than their male counterparts 
(Thomas & Elsohly, 2016).  Cannabis is comprised of over 400 known chemical compounds 
such as terpenes, flavonoids, alkaloids, and cannabinoids (Fisar, 2009).  
Cannabinoids, Phytocannabinoids, and Synthetic Cannabinoids 
 Cannabinoids are single molecules and are the terpenophenolic (i.e., part terpene, part 
phenol) components of Cannabis sativa L. (Fisar, 2009; Gertsch et al., 2010). These molecules 
are classified into three categories: phytocannabinoids, endocannabinoids, and synthetic 
cannabinoids (Fisar, 2009). Phytocannabinoids are naturally occurring cannabinoids found in 
Cannabis sativa L. plants (Gertsch et al., 2010); endocannabinoids are endogenous cannabinoids 
(i.e., cannabinoids originating from an organism); and synthetic cannabinoids are synthesized 
cannabinoids (Fisar, 2009). There are more than 100 classified phytocannabinoids (Andre et al., 
2016; Elsohly et al., 2016), but the two most studied and abundant cannabinoids are 
tetrahydrocannabinol (THC) and cannabidiol (CBD) (Elsohly et al., 2016; Thomas & Elsohly, 
2016). THC is a partial agonist (Huestis et al., 2001), whereas CBD is an antagonist (i.e., 




negative allosteric modulators; decreases agonist affinity) at cannabinoid receptor 1 (CB1 or 
CBR1) and 2 (CB2 or CBR2) (Crippa et al., 2012; Laprairie et al., 2015). These cannabinoids and 
cannabinoid receptors are a part of the endocannabinoid system (ECS). 
Endocannabinoids and the Endocannabinoid System  
The ECS is found in all vertebrates and consists of endocannabinoids (i.e., endogenous 
cannabinoids) (Khan et al., 2016), cannabinoid receptors, and deactivating enzymes that bind and 
alter endocannabinoids (Jacobson et al., 2019; Lu & Mackie, 2016; Silver, 2019). 
Endocannabinoids are endogenous lipids that bind to cannabinoid receptors (Kayser et al., 2020; 
Lu & Mackie, 2016). The two most researched cannabinoid receptors in the ECS are the CB1 (or 
CBR1), which are primarily located in peripheral and central neurons (Freeman et al., 2019; 
Katona & Freund, 2012; Pertwee, 2008), and the CB2 (or CBR2) (Matsuda et al., 1990; Munro et 
al., 1993; Serrano & Parsons, 2011; Silver, 2019), which are mainly found in immune cells 
(Pertwee, 2008). The primary role of the ECS is to regulate brain function homeostasis (Woods, 
2007) and seems to be involved with regulating factors such as sleep (Pava et al., 2016) and 
affect (Lutz et al., 2015). Long-term cannabis use is associated with specific chronic effects 
(Freeman et al., 2019), such as cognitive impairments (Hall et al., 2014), psychotic symptoms 
(e.g., delusions) and disorders (Hall et al., 2014), and suicidal ideation (Borges et al., 2016). 
Furthermore, brain structural reductions in grey matter (Battistella et al., 2014), the prefrontal 
cortex, the hippocampus, and the cerebellum have also been linked with long-term cannabis use 
(Hall et al., 2014). In addition to chronic effects, cannabis use is also correlated with, and causes, 
various acute (i.e., short-term) reactions (Martin-Santos et al., 2012).  
 
 




Acute Effects of THC and CBD  
An acute effect develops shortly after initial exposure of each use and is short in duration 
(WHO, 2016). Cannabis can invoke both positive and negative acute effects (Martin-Santos et 
al., 2012; WHO, 2016). Various acute effects include anxiety and psychotic symptoms, working 
memory impairments, increased heart rate (WHO, 2016), and psychomotor function impairments 
(Broyd et al., 2016). Some factors reported to influence these short-term effects are mode of 
administration (e.g., inhalation, ingestion), previous cannabis use experience, environment, 
attitude, and dose (WHO, 2016). For instance, some studies have found that THC at lower doses 
may decrease anxiety, whereas higher doses may increase anxiety (Freeman et al., 2019; Hunault 
et al., 2009). Furthermore, there is interindividual variation in the acute effects of THC, meaning 
that different people will have different reactions to the same dosage of THC (Martin-Santos et 
al., 2012). In a systematic review by Freeman et al. (2019), limited studies were found on the 
acute effects of CBD. Although limited, CBD✄☞ acute effects reported in the literature include 
antipsychotic, anxiolytic, and sedative effects, but do not include effects on cognitive 
functioning, motor performance, or pulse rate (Batalla et al., 2014; Martin-Santos et al., 2012).  
Medicinal and Non-medicinal Cannabis Use 
 Medicinal cannabis use (also referred to as therapeutic cannabis use) refers to the use of 
cannabis in order to lessen symptoms or treat disease (Whiting et al., 2015). Medicinal cannabis 
use can be further divided into prescribed (i.e., with medical documentation; licensed) or self-
prescribed medicinal use (i.e., without medical documentation; un-licensed) (Han et al., 2018; 
Smith et al., 2019). Non-medicinal cannabis use (also known as recreational cannabis use) refers 
to the use of cannabis for purposes other than lessening symptoms or treating disease (e.g., 
enjoyment).  




Medicinal cannabis is commonly prescribed and self-prescribed for the following 
disorders/dysfunctions: anxiety, appetite, chronic pain, depression, epilepsy, nausea, sleep (e.g., 
insomnia), and Tourette syndrome (Whiting et al., 2015). A systematic review and meta-analysis 
by Koppel et al. (2014) examined the efficacy of medicinal cannabis by assessing the adverse 
effects that patients experience from cannabinoid use. Their meta-analysis found that 6.9% of 
patients stopped taking the medicinal cannabinoids due to the negative effects such as suicidal 
ideation, mood changes, and dizziness compared to 2.2% in the placebo group who discontinued 
due to reported adverse effects (Koppel et al., 2014).  
In addition, Lin et al. (2016) compared medicinal and recreational adult cannabis users in 
various domains. They found no differences in areas such as education and prevalence of 
cannabis use disorder. However, the researchers discovered that medicinal users engaged in less 
non-cannabis drug use than recreational users (Lin et al., 2016). They suggested that 
polysubstance usage may occur more frequently in recreational users than medicinal users (Lin 
et al., 2016).  
Simultaneous Polysubstance Use 
 Polysubstance co-use, or concurrent polysubstance use, refers to using more than one 
substance, but on separate occasions within a specified timeframe (e.g., last 30 days) (Davis et 
al., 2019). However, for people that use substances, there is a tendency to administer multiple 
substances simultaneously (i.e., consuming more than one drug in one session), which is usually 
referred to as simultaneous polysubstance use (SPU) (Barrett et al., 2006; Davis et al., 2019). 
One matter that may confound the comprehension of acute adverse reactions to cannabis is that 
individuals who consume cannabis also engage in SPU (Barrett, 2006). That is, individuals 
consume at least one other substance at the same time as cannabis. Among those that use 




cannabis, alcohol is the most common substance consumed simultaneously with cannabis (Brière 
et al., 2011; Pape et al., 2009), with one study showing that users reported using alcohol on 82% 
of the occasions where cannabis was used (Davis et al., 2019; Pape et al., 2009) 
There are various reported reasons in the literature for why people partake in SPU (e.g., 
the effects of other drugs or peer influences) (Olthuis et al., 2013). Researchers have suggested 
that people may also be inclined to engage in SPU to experience expected pharmacodynamic 
effects when consuming certain substances simultaneously (i.e., increasing wanted effects or 
decreasing unwanted effects from a drug by consuming another drug at the same time) (Leri et 
al., 2003; Olthuis et al., 2013). However, many studies show the opposite result   combining 
substances simultaneously often decreases the positive acute effects experienced and increases 
the likelihood of experiencing the negative acute effects of a drug (e.g., Fernández-Calderón et 
al., 2020; Lipperman-Kreda et al., 2017; Manwell et al., 2019). For instance, in a study 
conducted on rats, three behavioural tests were performed (i.e., Emergence test, Elevated Plus-
maze test, and Social Interaction test) to evaluate their anxiety and socially-related behaviour 
when THC was injected with nicotine (Manwell et al., 2019). The researchers concluded that the 
anxiolytic effects of THC, which are typically desired, decreased (e.g., rats spent less time in 
open spaces), and the anxiogenic effects of THC, which are generally undesired, increased (e.g., 
rats spent more ✌✠ ☎ ✠✟ ✌✆☎ ✁✆✠✝☎ ☎✝✂✄) (Crummy et al., 2020; Manwell et al., 2019). In relation 
to simultaneous alcohol and marijuana (SAM) use, Lee et al. (2017) found that university 
students who participated in SAM use reported more substantial acute effects for symptoms such 
as clumsiness and difficulty concentrating than young adults who consumed either alcohol or 
marijuana only. The young adults who engaged in SAM may have been more likely to 
experience acute adverse reactions due to the interactions between the ingested substances 




(Fernández-Calderón et al., 2020; Iudici et al., 2015). These interactions that occur due to SPU 
can result in antagonistic effects (i.e., decrease the efficacy of one or more drugs), synergistic 
effects (i.e., increase the effects of one or more drugs), or additive/noninteraction effects (i.e., the 
combined effects of all drugs used; Roell et al., 2017) (Alsherbiny & Li, 2018). Synergistic or 
additive effects in particular have been found to be the most strongly associated with acute 
adverse reactions (e.g., Chihuri et al., 2017; Meier & Hatsukami, 2016; Pape et al., 2009). 
Regarding the simultaneous use of THC and ethanol, the evidence varies on whether this 
substance combination produces synergistic or additive effects, however findings typically lean 
to synergistic, especially at higher doses (see Ballard & de Wit, 2011 for a brief summary). 
However, a few studies have shown neither synergistic nor additive effects when simultaneously 
using THC and ethanol products, which previous researchers have suggested is either due to 
THC lessening the acute effects from ethanol or decreasing the desire to consume more alcohol 
(e.g., Ballard & de Wit, 2011). Also, Cummings et al. (2020) conducted a cross-sectional study 
that surveyed young adult college students about their SAM use patterns. Although cannabis 
acute adverse reactions were not measured, they found that those that consumed marijuana and 
alcohol simultaneously were more likely to report academic problems compared to students who 
consumed these substances on separate occasions (Cummings et al., 2020). There is minimal 
research on the simultaneous use of cannabis with other drugs and how that is associated with 
acute adverse reactions to cannabis. To the best of our knowledge, studies have not yet evaluated 
the association between SPU cannabis users, particularly legal substances outside of alcohol, and 
the variation, frequency, and distress rating of acute adverse reactions to cannabis.  
 A study found that young adults with polysubstance use disorders were more likely to 
have certain mental health disorders than those that had an alcohol or cannabis use disorder 




(Salom et al., 2016). In addition to the positive correlation between SPU and various mental 
health disorders (Salom et al., 2016), several mental health disorders have also been discovered 
to be correlated with trait affect (Saxon et al., 2017). For example, studies have found that mental 
health disorders such as anxiety and depression have been positively associated with negative 
trait affect, and positive trait affect has been associated negatively with depression (Saxon et al., 
2017). This relationship may exist because mental health conditions, such as major depressive 
disorder, ✁✂✟ ✂  ☎✁✌ ✝✟☎✄☞ mood or affect or both (Centre for Addiction and Mental Health 
[CAMH], n.d.). Thus, these previous relationships highlight the need to investigate trait affect 
and its relationship with acute adverse reactions to cannabis. 
Positive and Negative Affect 
 Watson et al. (1988) defined affect as either a state (i.e., how an individual feels at any 
given time) or trait (i.e., how an individual feels on average, or in general) and is commonly 
categorized into positive affect (PA) and negative affect (NA).1 Trait PA is defined as the 
tendency to respond positively to the environment (e.g., general tendency to feel excitement), 
and inversely, trait NA is the tendency to respond negatively to the environment (e.g., general 
tendency to feel irritable) (Clark et al., 1989; Naragon-Gainey et al., 2018; Watson et al., 1988). 
Watson et al. (1988) show that PA and NA are statistically independent of each other (i.e., 
orthogonal factors) (Watson, 1988). To illustrate, an individual can have a high PA and NA, high 
PA with low NA, low PA and NA, or low PA with high NA.  
Although affect has shown intraindividual variation, there is also evidence that affect is 
relatively stable ov☎☛ ✂ ✁☎☛☞✝✟✄☞ ✂✠ ☎✌✠ ☎ (Naragon-Gainey et al., 2018). Naragon-Gainey et al. 
 
1
 Previous authors have raised concerns about terminology inconsistency in the literature between 
affect, emotion, and mood (Pressman & Cohen, 2005).  




(2018) suggest that intraindividual examination may identify contributors for changes in a 
☞✁☎✁✠ ✠✁ ✁☎☛☞✝✟✄☞ affect at any given moment. Comparably, the interindividual assessment may 
identify individuals who are more susceptible to having particular types of affective experiences 
over other individuals (e.g., sadness) (Naragon-Gainey et al., 2018). Evolutionary-based 
explanations have been used to explain between-person variability in affect (Naragon-Gainey et 
al., 2018; Watson et al., 1999). Specifically, affect has been described as adaptive in that having 
high negative affectivity increases the tendency to avoid harmful situations, whereas positive 
affectivity increases the tendency to seek out rewarding experiences (Naragon-Gainey et al., 
2018; Watson et al., 1999). PA is related to various mental health outcomes, such as higher 
subjective and psychological well-being levels and a lower frequency of suicide ideation 
(Teismann et al., 2019). Negative affect is also associated with cognitive impairments, such as 
decreased memory recall of stressful experiences (Ma-Kellams et al., 2016), and both positive 
and negative affect have been linked to substance use (Serafini et al., 2016; Wills et al., 1999). 
For example, in outpatient treatment substance users, Serafini et al. (2016) found that PA scores 
were positively associated with the number of days abstinent from their abused substance. In a 
longitudinal study following adolescent substance use (i.e., tobacco, alcohol, and marijuana), NA 
was positively associated with substance use, and PA was found to be negatively associated with 
substance use (Wills et al., 1999). Research has not yet investigated the association between 
general trait affect and the experience of the variation, frequency, and distress rating of acute 
adverse reactions to cannabis.  
In addition to substance use abstinence, affect has been linked with mood disorders such 
as depression and anxiety (Riskind et al., 2013). On a chemical level, the individual levels of 
certain neurotransmitters may partly explain this relationship between affect and mood disorders. 




For instance, a study conducted by William and colleagues (2006) on a small sample of males (n 
= 23) revealed that serotonin (5-HT) blood levels were positively associated with PA (however, 
no relationship was found between 5-HT and NA in this same study; William et al., 2006). Yet, 
the authors noted earlier studies that showed that negative affect was negatively associated with 
5-HT (Williams et al., 2006). Some mental health disorders, such as clinical depression, were 
found to be negatively associated with 5-HT levels, which has been explained, and termed by 
researchers as the serotonin hypothesis (i.e., lower 5-HT activity hypothesized as a partial cause 
of depression) (Cowen & Browning, 2015), In addition to 5-HT, the hormone cortisol has also 
been found to be associated with trait affect. Although previous authors have noted the mixed 
findings (Miller et al., 2016), a few studies have shown that trait PA was negatively associated 
with cortisol levels (e.g., Hoyt et al., 2015), and trait NA was positively associated with cortisol 
levels (e.g., Piazza et al., 2013). Similar to the 5-HT literature, cortisol has also been linked to 
mental health disorders, such as anxiety. In a longitudinal study, Adam et al. (2014) examined 
the relationship between salivary cortisol and anxiety disorders annually over a six-year period 
and discovered that cortisol was positively associated with anxiety disorder onset; this 
association was particularly strong in predicting the onset of social anxiety disorders. These 
chemical (i.e., 5-HT and cortisol) relationships discussed may offer a biological explanation as to 
why affect is associated with some mental health disorders.  
Not only has NA been found to be associated with psychological and chemical 
components, but previous studies have also shown that NA is associated with human 
physiological components such as body weight and body mass index (Oinonen & Mazmanian, 
2001; Pasco et al., 2013). For example, Oinonen and Mazmanian (2001) found that young adult 
women with higher BMIs were more likely to have lower depression, anxiety, and negative 




affect scores. These earlier findings emphasize the need to explore the relationship between 
physiological components, such as body composition, and acute adverse reactions to cannabis. 
Body Composition 
 Yu et al. (2013) defined absolute body weight as the composition of adipose (i.e., fat) 
mass and adipose-free mass (i.e., fat-free mass; FFM). Adipose tissue is comprised of visceral 
adipose tissue (VAT) and subcutaneous adipose tissue (SAT) (Shuster et al., 2012). The purpose 
of adipose tissue is to store energy and secrete hormones into the blood through endocrinological 
signalling (Shuster et al., 2012). Body mass index (BMI) is an anthropometric measure (e.g., 
body mass, body fat) (Duren et al., 2008; Martin-Calvo et al., 2016) and is calculated by dividing 
weight by height squared (e.g., kg/m2) (Wells & Fewtrell, 2006). A meta-analysis conducted in 
2016 reported that BMI was positively correlated (r2 for a 95% CI ranged from 0.32 to 0.91) 
with body fat percentage (BFP) (Martin-Calvo et al., 2016). However, BMI does not differentiate 
FFM (i.e., muscle, bone, organs, and extracellular fluid) from adipose tissue (i.e., fat tissue) (Yu 
et al., 2013). Despite this limitation, BMI is the most popular substitute for predicting BFP 
indirectly (Ranasinghe et al., 2013). While BMI is commonly used as a predictor of body fat 
percentage (i.e., higher BMI predicting higher BFP), ideally, other measures that are more 
accurate should be used in conjunction with BMI to increase validity and reliability when 
measuring BFP, such as a skinfold calliper measurement, bio-electrical impedance analysis 
(BIA), and dual-energy X-ray absorptiometry (DEXA) (Harvard, 2020).  
A human body✄☞ tolerance to alcohol (i.e., ethanol) is determined by numerous factors, 
including body weight and BFP. Body weight affects alcohol tolerance in that the more one 
weighs, the higher tolerance to alcohol effects one may experience. Inversely, BFP affects 
alcohol tolerance in that higher BFP is associated with lower tolerance to alcohol✄s acute effects 




(Cedarbaum, 2012). This relationship occurs because alcohol is not fat-soluble, which results in 
higher blood alcohol levels (BAL) as body fat percentage increases (Cederbaum, 2012). Due to 
these mechanisms, women are at an increased risk for alcohol toxicity as women tend to be 
lower in body weight and have higher body fat percentages than men (Cederbaum, 2012). 
Contrarily, endocannabinoids like THC and CBD are highly lipid-soluble (Basu et al., 2014); 
therefore, cannabinoids are soluble in fat. Nevertheless, there is no research to our knowledge 
investigating the relationship between acute adverse effects to cannabis and body weight and 
BMI. 
Gaps in the Literature 
 Previous researchers investigating predictors of acute adverse reactions to cannabis, such 
as Lafrance et al. (2020), suggested that because their predictors only accounted for a maximum 
of 25% of the variance, there must be other potential predictors yet to be identified. To our 
knowledge, there have been no studies that have investigated the associations between SPU, trait 
affect, and body composition with the number, frequency, and distress rating of acute adverse 
reactions to cannabis. 
Current Investigation 
The current study will add to this existing literature by assessing the relationship between 
three facets of acute adverse reactions to cannabis and each of the following: simultaneous 
polysubstance use and trait affect. Guided by the literature, the following main research 
questions will be investigated:  
1. Simultaneous Polysubstance Use Comparisons and Associations 
a. Are there significant differences in the acute adverse reactions to cannabis (i.e., 
measured by: i. the total number of different acute adverse reactions experienced, 




ii. the average frequency of acute adverse reactions experienced, and iii. the 
average distress ratings from acute adverse reactions) between participants that 
have engaged in the simultaneous polysubstance use of cannabis and alcohol at 
least once in their lifetime, and participants that have never engaged in 
simultaneous polysubstance use of cannabis and alcohol? 
b.  Are there significant differences in the acute adverse reactions to cannabis 
between participants who have engaged in simultaneous polysubstance use of 
cannabis and nicotine at least once in their lifetime, and participants who have 
never engaged in simultaneous polysubstance use of cannabis and nicotine? 
c. Is simultaneous polysubstance use of cannabis and alcohol frequency (i.e., the 
percentage of cannabis uses in which alcohol was also used) associated with acute 
adverse reactions to cannabis? 
d. Is cannabis and nicotine simultaneous polysubstance use frequency (i.e., the 
percentage of cannabis uses in which nicotine was also used) associated with 
acute adverse reactions to cannabis? 
2. Trait Affect Associations 
a. Is trait positive affect associated with acute adverse reactions to cannabis?  
b. Is trait negative affect associated with acute adverse reactions to cannabis?  
3. Trait Affect Predictions 
a. Taking into account the covariates age, gender, and cannabis consumption 
frequency, how much variation can be explained in the acute adverse reactions to 
cannabis by adding trait positive affect. 




b. Taking into account the covariates age, gender, and cannabis consumption 
frequency, how much variation can be explained in the acute adverse reactions to 
cannabis by adding trait negative affect. 
Guided by the literature, the following exploratory research questions will be investigated: 
1. Body Composition Associations 
a. Is body weight associated with acute adverse reactions to cannabis? 
b. Is body mass index associated with acute adverse reactions to cannabis?  
Main Hypotheses 
The following hypotheses were generated from the research questions listed above: 
1. Simultaneous Polysubstance Use Comparisons and Associations 
a. The group of participants who have engaged in simultaneous polysubstance use of 
cannabis and alcohol at least once in their lifetime will have significantly higher 
mean acute adverse reaction scores to cannabis (i.e., measured by: i. the total 
number of different acute adverse reactions experienced, ii. the average frequency 
of acute adverse reactions experienced, and iii. the average distress ratings from 
acute adverse reactions) than the group of participants who have never engaged in 
simultaneous polysubstance use of cannabis and alcohol in acute adverse 
reactions to cannabis. 
b. The group of participants who have engaged in simultaneous polysubstance use of 
cannabis and nicotine at least once in their lifetime will have significantly higher 
mean than the group of participants who have never engaged in simultaneous 
polysubstance use of cannabis and nicotine in acute adverse reactions to cannabis. 




c. Simultaneous polysubstance use of cannabis and alcohol frequency will have a 
positive relationship with acute adverse reactions to cannabis.  
d. Simultaneous polysubstance use of cannabis and nicotine frequency will have a 
positive relationship with acute adverse reactions to cannabis.  
2. Trait Affect Associations 
a. Trait positive affect will have a negative relationship with acute adverse reactions 
to cannabis.  
b. Trait negative affect will have a positive relationship with acute adverse reactions 
to cannabis.  
3. Trait Affect Predictions 
a. Taking into account the covariates age, gender, and cannabis consumption 
frequency, the addition of trait positive affect will explain a statistically greater 
amount of the variation in predicting acute adverse reactions to cannabis.  
a. Taking into account the covariates age, gender, and cannabis consumption 
frequency, the addition of trait negative affect will explain a statistically greater 
amount of the variation in predicting acute adverse reactions to cannabis.  
Exploratory Hypotheses 
The hypotheses below were created from the exploratory research questions listed above: 
1. Body Composition Associations 
a. Body weight will have a negative relationship with acute adverse reactions to 
cannabis (i.e., measured by: 1. the total number of different acute adverse 
reactions experienced, 2. the average frequency of acute adverse reactions 
experienced, and 3. the average distress ratings from acute adverse reactions).  








Altogether, 720 participants completed the test battery. However, 156 were removed 
from the database due to not using cannabis at least once in their lifetime. An additional 94 were 
removed due to non-purposeful responding (i.e., receiving an Infrequency score higher than 3). 
Another 13 participants were omitted because they were not currently living in Canada at the 
time of the study. Lastly, one more participant was removed from the database as they did not 
provide their age. In Canada, and dependent on the province or territory, the lowest age possible 
that someone can legally purchase and consume cannabis is 18. After all removal stages, 456 
participants remained in the database, including 309 participants from the general public and 147 
from the university sample. Participants from the general public were primarily employed full-
time (61.9%), and many had either completed an undergraduate degree (22.3%) or a college 
degree (21.4%). The university sample was employed mainly part-time (61.2%), ✆✠✌✆ ✁☞✝ ☎
✏✟✝☎☛✞☛✂✝✏✂✌☎✄ ☎☎✠✟✞ ✌✆☎ ✆✠✞✆☎☞✌ ✂☎✡☎✂ ✝  ☎✝✏✁✂✌✠✝✟ ✁✝ ✁✂☎✌☎✝ ✟ ✁.1%). Additionally, the final 
combined sample was 64.1% female and was predominately White (82.2%). Table 1 presents the 










Table 1  
 
Demographic Characteristics of Participants (N = 456) 
Characteristic M(SD) Frequency % 
Age 29.26 (10.07)   
Sex    
 Female  291 (64.1%) 
 Male  159 (35.1%) 
 I do not identify with the options listed  1 (0.2%) 
 Prefer not to say  2 (0.4%) 
Gender    
 Female  286 (62.7%) 
 Male  160 (35.2%) 
 Non-binary  7 (1.5%) 
 Transgender  0 (0%) 
 I do not identify with the options listed  1 (0.2%) 
 Prefer not to say  1 (0.2%) 
Race/Ethnicity    
 Asian  25 (5.5%) 
 Black  7 (1.5%) 
 Caucasian (White)  374 (82.2%) 
 Hispanic/Latino/Latina/Latinx  3 (0.7%) 
 Indigenous (First Nations, Métis, or Inuit)  34 (7.5%) 
 Middle Eastern  2 (0.4%) 
 I do not identify with the options listed  9 (2.0%) 
 Prefer not to say  1 (0.2%) 
Sampling    
 General public  309 (67.8%) 
 University students  147 (32.2%) 
Nationality (i.e., country citizenship)    
 Canadian  419 (91.9%) 
 Canadian with multiple citizenship  27 (5.9%) 
 None of the above  10 (2.2%) 
Country of Residence (Majority of Life)    
 Canada  442 (96.9%) 
 Not in Canada  14 (3.1%) 
Province or Territory Residence (n = 309)a    
 Alberta  110 (35.5%) 
 British Columbia  15 (4.8%) 
 Manitoba  80 (25.8%) 
 New Brunswick  2 (0.6%) 
 Newfoundland and Labrador  2 (0.6%) 
 Northwest Territories  0 (0%) 
 Nova Scotia  4 (1.3%) 
 Ontario  91 (29.4%) 
 Prince Edward Island  0 (0%) 
 Quebec  4 (1.3%) 
 Saskatchewan  1 (0.3%) 
 Yukon  0 (0%) 
aItem surveyed from general public sample only. 




The mean age of cannabis use onset was 17.66 years old (SD = 5.01), ranging from 10 to 
49 years of age. Most participants reported consuming a THC dominant cannabis product (i.e., a 
higher amount of THC than CBD) most frequently during their cannabis use sessions (63.4%), 
5.7% of participants reported consuming a CBD dominant cannabis product (i.e., a higher 
amount of CBD than THC) most of the time, 15.4% of participants reported consuming a 
balanced cannabis product (i.e., containing a ☞✠ ✠✂✂☛ ✂ ✝✏✟✌ ✝  ☎✝✌✆  ✁✂ ✂✟✝ ✂✄☎✠ ✁✄✂✂✂✟✁☎✝
✆✝✆✄✞ most of the time, and 15.6% of participants reported that they were unsure of the 
cannabinoid profile they most frequently consumed in their cannabis products. The average 
frequency of cannabis consumption in the last week (i.e., 7 days) was 2.96 days (SD = 2.97), in 
the last month (i.e., 4 weeks) was 12.16 days (SD = 12.11), and in the last 3 months (i.e., 12 
weeks) was 35.19 days (SD = 35.73). The most common method for cannabis consumption was 
inhalation (e.g., smoking) (74.6%, n = 340), followed by ingestion (e.g., edibles) (25.2%, n = 
115), then absorption (e.g., topicals) (0.2%, n = 1).  
The primary purpose of cannabis consumption most of the time for participants was 
mainly or always for non-medicinal or recreational purposes (58.7%, n = 267), followed by equal 
consumption for recreational and medicinal purposes (29.5%, n = 134). Mainly or always for 
medicinal or therapeutic reasons was the least endorsed reason for cannabis consumption 
(11.9%, n = 54). For participants that reported consuming cannabis for medicinal or therapeutic 
reasons, the dominant three reasons were for anxiety (89.9%, n = 169), followed by stress 
(81.9%, n = 154), then insomnia (i.e., a sleep disorder characterized by sleeplessness) (74.5%, n 
= 140). Most participants reported only being around one other person most of the time while 
consuming cannabis (48.6%, n = 221), and most participants consumed cannabis inside their 
own home/apartment (61.8%, n = 282).  





Demographic Information Questionnaire 
Data regarding the participants✄ age, sex, gender, weight, height, ethnicity, marital status, 
religion, and level of education attained were collected. BMI was calculated using the weight and 
height collected from participants (see Appendix A). 
The Cannabis Reason, Age, Frequency, Type, and Setting Questionnaire (CRAFTS-Q) 
 The CRAFTS-Q is a newly created 20-item self-report tool, developed by the authors, to 
collect data regarding the reason for cannabis use (i.e., medicinal or recreational), age of first use 
for cannabis use, frequency, mode of consumption (e.g., edibles), cannabinoid-type (e.g., THC 
dominant), the status of cannabis use (i.e., regular and/or current cannabis user), and setting (i.e., 
the environment of initial cannabis consumption and effects experienced) (see Appendix B). 
Initial draft questions were administered to four respondents from various fields of study (i.e., 
psychology, history, and engineering) where respondents verbalized their mental processes when 
providing their answers. Items were edited based on feedback and were re-administered to two of 
the original respondents. With the finalized questions, participants were first presented with the 
following instructions: ✁Please read the definition for Cannabis provided below. Additionally, 
some examples of common Cannabis terminology and products have been provided along with 
the definition . The definition of Cannabis provided to participants was as follows: ✁Cannabis 
(e.g., marijuana, weed, pot, hash/hashish, THC, CBD) refers to the generic name for drugs or 
compounds that come from plants belonging to the genus ✁✂✄✄✂☎✆✝ ✞ Following the definition, 
participants showed their comprehension of the meaning using a 3-point ☞✁✂✂☎✠  ☛✝  ✁ ✁No, I 
✆✂✡☎ ✟✝✌ ☛☎✂✝ ✌✆☎ ✝☎ ✠✟✠✌✠✝✟  ✝☛ ✂✂✟✟✂☎✠☞ ☞✌✂✌☎✝ ✂☎✝✡☎✄ ✌✝ ✟ ✁✠☎☞✠ ✂✟✝ ✡ ✏✟✝☎☛☞✌✂✟✝ ✌✆☎ ✝☎ ✠✟✠✌✠✝✟
 ✝☛ ✂✂✟✟✂☎✠☞ ☞✌✂✌☎✝ ✂☎✝✡☎✄✁ ☛✂☛✌✠✁✠✁✂✟✌☞ ✌✆✂✌ ☞✁✝☛☎d a zero or one on this item were excluded 




from the final analysis of this questionnaire. The following question participants received 
concerned their lifetime cannabis use. Participants that endorsed ✁ ✝✄ ✟✠✁☎✁✠ ✟☎✡☎☛ ✏☞☎✝ ✁✂✟✟✂☎✠☞
in their lifetime) did not answer any more questions remaining in the CRAFTS-Q. Participants 
that endorsed ✁✠☎☞✄ ✟✠✁☎✁✠ ✆✂✡☎ ✏☞☎✝ ✁✂✟✟✂☎✠☞ ✠✟ ✌✆☎✠☛ ✂✠ ☎✌✠ ☎✞ ✆ere asked to complete the 
remaining 18 items in the questionnaire. The remaining questions had ☎✠✌✆☎☛ ✂ ☎✠✟✂☛✍ ✁ ✝✄ ✝☛
✁✠☎☞✄, open response, or a 3 to 9-point scale response format. Age of first use was assessed with 
one item, two items each to evaluate the status of cannabis user, cannabinoid-type, and mode of 
consumption; frequency of cannabis consumption was assessed with three items, and four items 
were used to determine reason and setting (i.e., environment) of cannabis use.  
Simultaneous Polysubstance Use ✁ Cannabis, Alcohol and Nicotine Questionnaire (SPU-
CAN) 
 The SPU-CAN is a newly created 7-item self-report tool, developed by the authors, that 
evaluates lifetime occurrence and frequency of cannabis SPU with alcohol or nicotine (see 
Appendix C). Similar to the CRAFTS-Q, initial draft questions were administered to four 
respondents from various fields of study (i.e., psychology, history, and engineering). The 
respondents were asked to verbalize their mental processes when providing their answers. Items 
were edited based on feedback and re-administered to two original respondents to confirm the 
finalized items. With the finalized items, participants were presented with the following 
✠✟☞✌☛✏✁✌✠✝✟☞✝ ✁☛✂☎✂☞☎ ☛☎✂✝ ✌✆☎ ✝☎ ✠✟✠✌✠✝✟  ✝☛ Cannabis provided below. Additionally, some 
examples of common Cannabis terminology and products have been provided along with the 
definition ✞ The definition of Cannabis provided to participants was ✂☞  ✝✂✂✝✆☞✝ ✁Cannabis (e.g., 
marijuana, weed, pot, hash/hashish, THC, CBD) refers to the generic name for drugs or 
compounds that come from plants belonging to the genus Cannabis ✞ The following question 




participants received was related to their lifetime cannabis use. Participants that endorsed ✁ ✝✄
(i.e., never used cannabis in their lifetime) did not answer any more questions remaining in the 
SPU-CAN. Participants that endorsed ✁✠☎☞✄ ✟✠✁☎✁✠ ✆✂✡☎ ✏☞☎✝ ✁✂✟✟✂☎✠☞ ✠✟ ✌✆☎✠☛ ✂✠ ☎✌✠ ☎✞ ✆ere 
asked to complete the remaining 6 items in the questionnaire. The remaining questions either had 
✂ ☎✠✟✂☛✍ ✁ ✝✄ ✝☛ ✁✠☎☞✄✠ ✝☛ ✂ numeric open-response format. The remaining six questions 
consisted of two separate lifetime-use questions, one for alcohol and the other for nicotine, that 
had ✂ ✁ ✝✄ ✟☎✁✞✁✠ ✟☎✡☎☛ ✁✝✟☞✏ ☎✝ ✂✂✁✝✆✝✂ ✠✟ ✌✆☎✠☛ ✂✠ ☎✌✠ ☎✞ ✝☛ ✁✠☎☞✄ response format. Two more 
questions involved asking about their SPU with cannabis, separately for alcohol and nicotine; 
again, ✆✠✌✆ ✂ ☎✠✟✂☛✍ ✁ ✝✄ ✝☛ ✁✠☎☞✄ ☛☎☞✁✝✟☞☎  ✝☛ ✂✌✁ ☛✂☛✌✠✁✠✁✂✟✌☞ were asked two questions about 
the frequency of their SPU with cannabis, independently for alcohol and nicotine, using a 
numeric, open-response format by reporting their percentage of cannabis simultaneous 
polysubstance use from 1-100% (i.e., 100% indicating that they consume alcohol or nicotine 
every time they consume cannabis).  
Adverse Reactions Scale (ARS; Lafrance et al., 2020) 
 The ARS is a 26-item self-report tool that measures the total number of different acute 
adverse reactions to cannabis, the frequency of each adverse acute response to cannabis, and the 
distress associated with each acute adverse reaction to cannabis (see Appendix D). Participants 
are requested to indicate if they have experienced any of the 26 listed adverse reactions to acute 
cannabis intoxication (e.g., anxiety, paranoia, vomiting) with a binary ✁ ✝✄ ✝☛ ✁✠☎☞✄ ✌✝  ☎✂☞✏☛☎
the total number of different acute adverse reactions experienced. For each acute adverse 
☛☎✂✁✌✠✝✟ ✌✆✂✌ ✁✂☛✌✠✁✠✁✂✟✌☞ ☛☎☞✁✝✟✝ ✆✠✌✆ ✁✠☎☞✄ to, they also receive two follow-up questions to 
measure the frequency and distress for each of their experienced acute adverse reactions. The 
frequency of the acute adverse reactions is measured by asking the participant to report the 




percentage of times the acute adverse reaction was experienced out of all of the times that they 
✆✂✡☎ ☎✡☎☛ ✏☞☎✝ ✁✂✟✟✂☎✠☞ ✟☎✁✞✁✠ ✁Approximately what percentage of the time that you use cannabis 
do you experience anxiety?✄✞✁  ✆☎ ✁☎☛✁☎✠✡☎✝ ✝✠☞✌☛☎☞☞  ✝☛ ☎✡☎☛✍ ☎✟✝✝☛☞☎✝ ✂✁✏✌☎ ✂✝✡☎☛☞☎ ☛☎✂✁✌✠✝✟
to cannabis is measured by having the participant rate their distress level on a 5-point Likert-type 
☞✁✂✂☎✠  ☛✝  ✁ ✁ ✝✌ ✂✌ ✂✂✂ ✝✠☞✌☛☎☞☞✠✟✞✄ ✌✝   ✁✎☎✡☎☛☎✂✍ ✝✠☞✌☛☎☞☞✠✟✞✄ ✟☎✁✞✁✠ On average, how 
distressing was experiencing anxiety while under the influence of cannabis✁✄✞✁ The authors have 
☞✏✞✞☎☞✌☎✝ ✌✆✂✌ ✌✆☎ ✂✁✏✌☎ ✂✝✡☎☛☞☎ ☛☎✂✁✌✠✝✟☞ ✝  ✁☎✝✝✍ ✆✏  ✠✟✞✄✠ ✁✟✏ ☎✟☎☞☞✄ ✂✟✝ ✁✏✟☞✌☎✂✝✠✟☎☞☞✄
could be removed from the scale as these reactions may not be perceived as negative to cannabis 
users. The number of acute adverse reactions for each participant was calculated by counting 
each adverse reaction endorsed; the average frequency of acute adverse reactions was calculated 
by averaging the participants✄ frequency rating for each acute adverse reaction the participant 
endorsed; and like frequency, average distress ratings for each participant were calculated by 
averaging the distress rating for every acute adverse reaction endorsed. Internal consistencies 
reported by Lafrance et al. (2020) were .90, .75, and .99 for prevalence, frequency, and distress, 
respectively. ✂✏☛✌✝☞✠☞ ✡✂✂✏☎☞ ✆☎☛☎ ☞ ✂✂✂☎☛ ✌✆✂✟ ✄☎✆ ✟✁✁, and each variable was normally 
distributed (Lafrance et al., 2020). No estimates of validity were provided for this scale.  
Positive and Negative Affect Schedule (PANAS; Watson et al., 1988) 
 The PANAS contains two 10-item affect scales, one scale measures NA and the other 
measuring PA (see Appendix E). Participants are requested to rate how they feel in general, on 
average, on 20 affect adjectives. Ten PA (e.g., Excited) and ten NA (e.g., Irritable) adjectives 
were rated on a 5-point Likert-type scale, from 1 ✁Very slightly or not at all✄ ✌✝ 5 ✁Extremely✄ 
(Watson et al., 1988). Watson et al. (1988) reported the general time frame (i.e., lifetime 
perceived average of affect) for the PA scale to have a .88 internal consistency and the general 




time frame for the NA scale to have a .87 internal consistency. The test-retest reliabilities for the 
general time frame, with 8-weeks between each test, were .68 and .71 for positive and negative 
affect, respectively (Watson et al., 1988).  
Social Desirability Scale ✁ Personality Research Form (PRF-D; Jackson, 1987) 
The PRF-D consists of sixteen items that measure socially desirable responding (see 
Appendix F✞✁  ✆☎ ☞✁✂✂☎ ✆✂☞ ✂ ✁✌☛✏☎✄ ✂✟✝ ✁ ✂✂☞☎✄ ☛☎☞✁✝✟☞☎  ✝☛ ✂✌  ✝☛ ✂✂✂ ☞✠✂✌☎☎✟ ✠✌☎ ☞ ✟☎✁✞✁✠ ✁✡ 
☞✝ ☎✝✟☎ ✞✂✡☎  ☎ ✌✝✝  ✏✁✆ ✁✆✂✟✞☎✠ ✡ ✆✝✏✂✝ ✌☎✂✂ ✆✠ ✄✞✁ Jackson (1987) reported a high test-retest 
reliability (.81) and internal consistency (.83).  
Infrequency Scale ✁ Personality research Form (PRF-IN; Jackson, 1987) 
The PRF-IN consists of sixteen items that measure non-purposeful responding (see 
Appendix G✞✁  ✆☎ ☞✁✂✂☎ ✆✂☞ ✂ ✁✌☛✏☎✄ ✂✟✝ ✁ ✂✂☞☎✄ ☛☎☞✁✝✟☞☎  ✝☛ ✂✌  ✝☛ ✂✂✂ ☞✠✂✌☎☎✟ ✠✌☎ ☞ ✟☎✁✞✁✠
✁Sometimes I feel thirsty or hungry✄✞✁ Jackson (1987) reported a moderate test-retest reliability 
(.46). The author of this scale describes a score of four or more as indicative of non-purposeful 
or careless responding; thus, participants in this study who scored greater than three were 
removed from further analyses. Internal consistency is low for this scale due to the low 
endorsement rates. There is little or no variance because most respondents will either endorse a 
small number of the items or none at all.  
Cannabis Use During COVID-19 Restrictions Information Questionnaire 
 On March 11th, 2020, WHO declared a COVID-19 pandemic. Due to this unique time in 
cannabis research, data regarding the participants✄ frequency of cannabis use, first use of 
cannabis, and mental health during the COVID-19 restrictions was also collected (see Appendix 
H). Participants were presented the  ✝✂✂✝✆✠✟✞ ✠✟☞✌☛✏✁✌✠✝✟☞✝ ✁☛✂☎✂☞☎ ☛☎✂✝ ✌✆☎ ✝☎ ✠✟✠✌✠✝✟s for 
Cannabis and COVID-19 restrictions provided below. Additionally, some examples of common 




Cannabis terminology and products have been provided along with the definition ✞ Like the 
CRAFTS-Q and SPU-CAN questionnaire, the definition of Cannabis provided to participants 
was ✂☞  ✝✂✂✝✆☞✝ ✁Cannabis (e.g., marijuana, weed, pot, hash/hashish, THC, CBD) refers to the 
generic name for drugs or compounds that come from plants belonging to the genus ✁✂✄✄✂☎✆✝ ✞
The definition of COVID-19 restrictions was ✂☞  ✝✂✂✝✆☞✝ ✁Refers to a period of time of measures 
set in place (e.g., physical distancing, travel bans, closed borders, lockdowns, etc.) to restrict 
human contact because of the Coronavirus disease 2019 (COVID-19) disease which was 
upgraded to pandemic status on March 11th, 2020 by the World Health Organization (WHO)✄✁
This collected information is not related to our main research questions, however, we deemed it 
appropriate as we realize the timing of our data collection may have an affect on the results of 
this study, such as cannabis use frequency (e.g., increased stress and layoffs may increase 
cannabis use). 
Procedure 
This study was a cross-sectional design that required participants to complete an online 
self-report questionnaire. They were asked to complete the scales listed above. The university 
students were recruited from Lakehead University, and the general public were recruited across 
Canada. Online recruitment strategies occurred between November 2020 and February 2021. 
Recruitment strategies included emails sent to Lakehead University psychology courses (see 
Appendix I), poster advertisements (see Appendix J) on social media (i.e., Facebook, Instagram, 
and Reddit), online advertising websites (i.e., Kijiji), and on Sona Systems (i.e., a software to 
host research studies that the Psychology department at Lakehead University uses to advertise 
and recruit undergraduate psychology students). University students and the general public were 
invited to click a hyperlink that directed them to their relevant information letter and consent 




form (see Appendix K and L) which provided information about the procedure of the study, that 
participation is voluntary, they have the right to withdraw from the study at any point, and that 
their responses are anonymous. After reading the required information for informed consent, 
participants were then asked to consent to the ✁The Cannabis Experiences Study✄ ✟✠✁☎✁✠ The 
CAN-E Study). Following consent, participants responded to a questionnaire battery through a 
secured website service (i.e., SurveyMonkey) that included the self-report measures. After the 
participants completed the online questionnaire, they were provided with the appropriate 
debriefing letter (see Appendix M and N) that informed them of the purpose of the study, 
provided instructions on how to be compensated for their time (i.e., eGift card draw or one bonus 
mark towards an eligible Lakehead University course), and how to request a summary of the 
results. This study w✂☞ ✂✁✁☛✝✡☎✝ ☎✍ ✁✂✄☎✆☎✂✝ ✞✟✠✡☎☛☞✠✌✍✄☞ Research Ethics Board (#1468303).  
Data Analyses 
 The data were first examined for non-purposeful responding, outliers, and to verify the 
assumptions for independent samples t-tests, Pearson product-moment correlations and 
hierarchical multiple regressions before conducting any statistical procedure for the hypotheses. 
For the independent samples t-test, outliers (i.e., assessed via boxplots), normally distributed 
residuals (i.e., analyzed by inspecting a Normal Q-Q plot), and homogeneity of variances (i.e., 
examined ✆✠✌✆ ✁☎✡☎✟☎✄☞ ✌☎☞✌✞ were examined to determine if assumptions were violated. If 
homogeneity of variances was ✡✠✝✂✂✌☎✝ ✟✠✁☎✁✠ ✂ ☞✌✂✌✠☞✌✠✁✂✂✂✍ ☞✠✞✟✠ ✠✁✂✟✌ ✁☎✡☎✟☎✄☞ ✌☎☞✌✞✠ the Welch✄☞ 
t-test ✆✝✏✂✝ ☎☎ ✁✝✟✝✏✁✌☎✝ ✠✟☞✌☎✂✝ ✝  ✌✆☎ ✎✌✏✝☎✟✌✄☞ t-test. The assumptions for the Pearson 
product-moment correlations that were examined were outliers, linearity between both variables 
(i.e., determined by examining scatterplots), and normality between both variables (i.e., Normal 
Q-Q plots). Finally, the assumptions analyzed for the hierarchical multiple regression analyses 




were the following: outliers, linearity (i.e., scatterplots and partial regression scatterplots), 
independence of residuals (i.e., Durbin Watson statistic of approximately 2), normal distribution 
of residuals, homoscedasticity of residuals (i.e., linearity between studentized residuals and 
unstandardized predicted values), multicollinearity (i.e., tolerance values less than 0.1), leverage 
points (i.e., cases with leverage points greater than 0.2) (Huber, 1981), and influential points 
✟✠✁☎✁✠ ✂✝✝✄✄☞ ☎✠☞✌✂✟✁☎ ✞☛☎✂✌☎☛ ✌✆✂✟ ✆). As response bias issues may be more prevalent due to 
stigmatized topics being examined in this study, such as substance use and body weight, socially 
desirable responding was controlled by conducting ANCOVAs for the independent samples t-
tests, partial correlations for the Pearson product-moment correlations, and including social 
desirability as a covariate in the hierarchical multiple regressions. 
Due to the number of statistical tests (i.e., 30), a multiple-test correction, specifically the 
Benjamini-Hochberg correction, with a false-discovery rate set to .10, was implemented to 
control Type I errors (Benjamini & Hochberg, 1995). For example, using the Benjamini-
Hochberg correction in this study, a p-value of .034 would not be considered statistically 
significant as the equivalent Benjamini-Hochberg correction of this p value would approximately 
be .11. Therefore, a p-value greater than or equal to .034 is not statistically significant in these 
analyses. 
 Main Hypotheses. 
 Hypothesis 1a. An independent samples t-test analysis was used to investigate the mean 
differences between participants that have engaged in simultaneous polysubstance use of 
cannabis and alcohol at least once in their lifetime, and participants that have never engaged in 
simultaneous polysubstance use of cannabis and alcohol on the three dependent variables for 
acute adverse reactions to cannabis (i.e., the total number of different adverse reactions 




experienced, the average frequency of acute adverse reactions experienced, and the average 
distress ratings from the acute adverse reactions experienced).  
 Hypothesis 1b. Comparable to hypothesis 1a, an independent samples t-test analysis was 
conducted to examine the mean differences between participants that have engaged in cannabis 
and nicotine simultaneous polysubstance use at least once in their lifetime, and participants that 
have never engaged in cannabis and nicotine simultaneous polysubstance use on the three 
dependent variables used to measure acute adverse reactions to cannabis.  
 Hypothesis 1c. A Pearson product-moment correlation analysis was conducted to 
examine the association between simultaneous polysubstance use of cannabis and alcohol 
frequency and the three dependent variables used to measure acute adverse reactions to cannabis.  
 Hypothesis 1d. Similar to hypothesis 1c, a Pearson product-moment correlation analysis 
was performed to investigate the association between simultaneous polysubstance use of 
cannabis and nicotine frequency and the three dependent variables used to measure acute adverse 
reactions to cannabis.  
 Hypothesis 2a. Another product-moment correlation analysis was performed to 
investigate the association between trait positive affect and the three dependent variables used to 
measure acute adverse reactions to cannabis.  
 Hypothesis 2b. Similar to hypotheses 1c through 2a, a product-moment correlation 
analysis was done to examine the association between trait negative affect and the three 
dependent variables used to measure acute adverse reactions to cannabis.  
 Hypothesis 3a. Hierarchical multiple regression analyses were completed to analyze if 
trait positive affect predicted the three dependent variables used to measure acute adverse 
reactions to cannabis. Block one consisted of the covariates age (i.e., continuous variable), 




gender (i.e., nominal dichotomous variable), and frequency of cannabis consumption in the last 3 
months (i.e., continuous variable). Block two included trait positive affect (i.e., continuous 
variable). 
 Hypothesis 3b. Similarly, another hierarchical multiple regression analyses were used to 
investigate if trait negative affect predicted the three dependent variables used to measure acute 
adverse reactions to cannabis. Block one consisted of the covariates age, gender, and frequency 
of cannabis consumption in the last 3 months. Block two included trait negative affect (i.e., 
continuous variable). 
 Exploratory Hypotheses. 
 Hypothesis 1a. A product-moment correlation analysis was conducted to investigate the 
association between body weight and the three dependent variables used to measure acute 
adverse reactions to cannabis.  
 Hypothesis 1b. Another product-moment correlation analysis was performed to explore 
the relationship between BMI and the three dependent variables used to measure acute adverse 
reactions to cannabis. 
Results 
Data Screening 
 Before conducting the analyses to test the hypotheses, infrequent (i.e., non-purposeful) 
responding was examined for all participants using ✁✂☛✌✠✁✠✁✂✟✌✄☞ PRF-IN scores. Participants 
with PRF-IN scores greater than 3 were not included in the analyses of this study. Additionally, 
participants were omitted from the final analyses if they completed the study in less than 5 
minutes (i.e., average completion time was 30 minutes and 13 seconds).  
 




Scale Characteristics and Internal Consistencies 
 Where applicable, the mean, range, standard deviation, and internal consistency were 
examined for each scale used in the analyses (see Table 2).  
Table 2  
 
Scale Range, Means, Standard Deviations and Internal Consistencies  
Measure 
N M(SD) Internal 
Consistency 
 Scale (range possible)    
ARSa     
 Number of Different Acute Adverse 
 Reactions (0-26) 
453 7.13(4.45) .79 
 Average Frequency of Acute Adverse 
 Reactions (0-100%) 
456 8.28(9.13) .85 
 Average Distress Associated with 
 Acute Adverse Reactions (0-4) 
456 1.21(0.86) .79 
SPU-CANb    
 Cannabis with Alcohol (0-100%) 456 20.22(27.77)  
 Cannabis with Nicotine (0-100%) 456 21.05(36.91)  
PANASc    
 Positive Affect (10-50) 445 27.98(8.45) .92 
 Negative Affect (10-50) 443 20.08(7.91) .90 
Body Composition    
 Body Weight in Pounds 452 173.01(47.89)  
 Body Mass Index 451 26.84(6.34)  
PRFd    
 PRF-D (0-16) 452 10.97(2.99) .69 
 PRF-I (0-16) 456 0.32(0.61) .19e 
a 
Adverse Reactions Scale 
b 
Simultaneous Polysubstance Use   Cannabis, Alcohol, Nicotine 
c 
Positive and Negative Affect Schedule 
d
 Personality Research Form   Desirability and Infrequency 
e 











Simultaneous Polysubstance Use of Cannabis and Alcohol Comparisons  
 Hypothesis 1a.  
Total Acute Adverse Reactions. Participants that have consumed alcohol simultaneously 
with cannabis use at least once (M = 7.44, SD = 4.24, n = 371) had significantly higher total 
adverse reaction mean scores than participants who have never consumed alcohol simultaneously 
with cannabis (M = 5.77, SD = 4.10, n = 74), t(443) = 1.67, p = .002. To explore the potential 
role of response styles, an ANCOVA was conducted as well using social desirability as a 
covariate. The findings remained significant, F(1, 438) = 10.88, p = .001. 
 Average Frequency of Acute Adverse Reactions. Four outliers in the average frequency 
of acute adverse reactions experienced subscale were detected via boxplot. However, upon 
further examination for each case, and the large sample size, the outliers were included in the 
analyses. Levene✄☞ ✌☎☞✌  ✝☛ ☎ ✏✂✂✠✌✍ ✝  ✡✂☛✠✂✟✁☎ ☛☎✡☎✂✂☎✝ that the assumption of homogeneity of 
variances was violated (p = .005). Consequently, a Welch t-test was conducted. The Welch t-test 
revealed that there was not a statistically significant difference in the mean average frequency of 
acute adverse reactions between participants that have consumed alcohol simultaneously with 
cannabis at least once (M = 7.87, SD = 8.87, n = 374) and participants who have never consumed 
alcohol simultaneously with cannabis (M = 10.39, SD = 11.31, n = 74), t(90.70) = 1.82, p = .072. 
Additionally, after controlling for socially desirable responses via an ANCOVA and decreasing 
Type I errors through the Benjamini-Hochberg procedure, the mean differences for the average 
frequency of acute adverse reactions remained nonsignificant, F(1,441) = 4.31, p = .039. 
 Average Distress Rating of Acute Adverse Reactions. ✁☎✡☎✟☎✄☞ ✌☎☞✌  ✝☛ ☎ ✏✂✂✠✌✍ ✝ 
variance revealed that the assumption of homogeneity of variances was violated (p = .005). A 




Welch t-test was therefore conducted and revealed that there was not a statistically significant 
difference in the average mean distress rating of acute adverse reactions between participants 
that have consumed alcohol simultaneously with cannabis (M = 1.19, SD = 0.82, n = 367) and 
participants who have never consumed alcohol simultaneously with cannabis (M = 1.28, SD = 
1.03, n = 67), t(81.99) = .70, p = .484. This finding also remained nonsignificant when 
controlling for social desirability, F(1,427) = .95, p = .331. 
Simultaneous Polysubstance Use of Cannabis and Nicotine Comparisons  
 Hypothesis 1b.  
 Total Acute Adverse Reactions. The independent samples t-test revealed that there was 
not a statistically significant difference in the mean total of acute adverse reactions experienced 
between participants that have consumed nicotine simultaneously with cannabis (M = 7.7, SD = 
4.3, n = 196) and participants who have never consumed nicotine simultaneously with cannabis 
(M = 7.34, SD = 4.6, n = 100), t(294) = -.66, p = .508. Similarly for the analyses completed for 
hypotheses 1a, socially desirable responding was also used as a covariate and the findings 
remained nonsignificant (p = 1.00). 
 Average Frequency of Acute Adverse Reactions. Three outliers in the average frequency 
of acute adverse reactions experienced subscale were detected via boxplot. However, upon 
further examination of each case, and the large sample size, the extreme outliers were included in 
the analyses. The independent samples t-test revealed that there was not a statistically significant 
difference in the mean average frequency of acute adverse reactions experienced between 
participants that have consumed nicotine simultaneously with cannabis (M = 7.78, SD = 9.18, n = 
196) and participants who have never consumed nicotine simultaneously with cannabis (M = 
9.55, SD = 9.92, n = 101), t(295) = 1.53, p = .127. However, when controlling for social 




desirability, the average frequency of acute adverse reactions for participants who have never 
consumed nicotine simultaneously with cannabis was significantly higher than participants who 
have consumed both products simultaneously, F(1, 291) = 4.94 , p = .027. 
 Average Distress Rating of Acute Adverse Reactions. ✁☎✡☎✟☎✄☞ ✌☎☞✌  ✝☛ ☎ ✏✂✂✠✌✍ ✝ 
variance revealed that the assumption of homogeneity of variances was violated (p = .001). A 
Welch t-test was therefore conducted and revealed that there was not a statistically significant 
difference in the mean average distress rating of acute adverse reactions between participants 
that have consumed nicotine simultaneously with cannabis (M = 1.26, SD = 0.77, n = 192) and 
participants who have never consumed nicotine simultaneously with cannabis (M = 1.23, SD = 
0.94, n = 99), t(167.39) = -.31, p = .758. After controlling for social desirability, these mean 
differences remained nonsignificant, F(1, 285) < .0005, p = .989. 
Simultaneous Polysubstance Use of Cannabis and Alcohol Associations 
 Hypothesis 1c.  
Total Acute Adverse Reactions. The association between cannabis and alcohol 
simultaneous polysubstance use frequency and total acute adverse reactions was not statistically 
significant, r(454) = -.04, p = .351. Even after controlling for social desirability via partial 
correlation, the relationship between the percentage of cannabis uses in which alcohol was also 
used and total acute adverse reactions remained nonsignificant, rpartial(446) = -.04, p = .431. 
Please see Table 3 for a summary of the Pearson correlation statistics between total acute adverse 










Pearson Correlation Coefficients for Total Acute Adverse Reactions 
Variable Total Acute Adverse Reactions 
 r p 
Cannabis and Alcohol SPU Frequencya -.04 .351 
Cannabis and Nicotine SPU Frequencyb .10 .037c 
Trait PA -.09 .057 
Trait NA .31 < .0005* 
Body Weightd -.07 .133 
BMId -.05 .278 
a
Frequency represents the percentage of cannabis uses in which alcohol was also used 
b
Frequency represents the percentage of cannabis uses in which nicotine was also used 
c
Correlation did not maintain significance after Benjamini-Hochberg correction 
d
Variables for exploratory hypotheses 
* p < .001  
 
Average Frequency of Acute Adverse Reactions. Both variables, cannabis and alcohol 
simultaneous polysubstance use frequency and average frequency of acute adverse reactions, 
were not normally distributed when a Normal Q-Q plot was examined. However, as both 
variables have comparable distribution shapes (i.e., positive skewness) (Tabachnick & Fidell, 
2006) ✂✟✝ ✂☞ ✂ ☛☎✂☛☞✝✟✄☞ ✁✝☛☛☎✂✂✌✠✝✟ ✂✟✂✂✍☞✠☞ ✠☞ ☛✝☎✏☞✌ ✌✝ ✟✝☛ ✂✂✠✌✍ ✡✠✝✂✂✌✠✝✟☞ ✟Knief & 
Forstmeier, 2021✞✠ ✂ ☛☎✂☛☞✝✟✄☞ ✁✝☛☛☎✂✂✌✠✝✟ ✆✂☞ nonetheless conducted. A bivariate correlation 
found between cannabis and alcohol simultaneous polysubstance use and average frequency of 
acute adverse reactions was not significant, r(454) = -.01, p = .883. This finding also remained 
nonsignificant when controlling for social desirability, rpartial(449) = .004, p = .936. See Table 4 
for a summary of the Pearson correlation statistics between average frequency of acute adverse 










Pearson Correlation Coefficients for Average Frequency of Acute Adverse Reactions 
Variable Average Frequency of Acute Adverse Reactions 
 r p 
Cannabis and Alcohol SPU Frequencya -.01 .883 
Cannabis and Nicotine SPU Frequencyb .05 .326 
Trait PA -.07 .148 
Trait NA .35 < .0005* 
Body Weightc -.11 .021* 
BMIc -.05 .282 
a
Frequency represents the percentage of cannabis uses in which alcohol was also used 
b
Frequency represents the percentage of cannabis uses in which nicotine was also used 
c
Variables for exploratory hypotheses 
* p < .05 
 
Average Distress Rating of Acute Adverse Reactions. A bivariate correlation between 
cannabis and alcohol simultaneous polysubstance use frequency and average distress rating of 
acute adverse reactions experienced was not statistically significant, r(439) = .05, p = .258. After 
controlling for social desirability, this relationship remained nonsignificant, rpartial(434) = .06, p = 
.253. See Table 5 for a summary of the Pearson correlation statistics between average distress 
rating of acute adverse reactions experienced and each predictor variable.  
Table 5 
 
Pearson Correlation Coefficients for Average Distress Rating of Acute Adverse Reactions 
Variable Average Distress Rating of Acute Adverse 
Reactions 
 r p 
Cannabis and Alcohol SPU Frequencya .05 .258 
Cannabis and Nicotine SPU Frequencyb .10 .034c 
Trait PA -.06 .257 
Trait NA .24 < .0005* 
Body Weightd -.14 .004* 
BMId -.03 .520 
a
Frequency represents the percentage of cannabis uses in which alcohol was also used 
b
Frequency represents the percentage of cannabis uses in which nicotine was also used 
c
Correlation did not maintain significance after Benjamini-Hochberg correction 
d
Variables for exploratory hypotheses 
* p < .001  




 Simultaneous Polysubstance Use of Cannabis and Nicotine Associations 
 Hypothesis 1d.  
Total Acute Adverse Reactions. An association was not found between simultaneous 
polysubstance use of cannabis and nicotine frequency and total acute adverse reactions, when 
corrected with the Benjamini-Hochberg procedure, r(451) = .10, p = .037. Similar to hypothesis 
1c, a partial correlation was conducted to control for social desirability. After partialling out 
social desirability, the relationship between the percentage of cannabis uses in which nicotine 
was also used and total acute adverse reactions remained nonsignificant, rpartial(446) = .07, p = 
.163. 
 Average Frequency of Acute Adverse Reactions. Two outliers were detected via 
scatterplot. Though, upon more examination for both cases, and the large sample size, the 
outliers were included in the analyses as they were not suspected of being data-entry errors. Both 
variables, simultaneous polysubstance use of cannabis and nicotine frequency and average 
frequency of acute adverse reactions, were not normally distributed when a Normal Q-Q plot 
was examined.  However, both variables have similar ✝✠☞✌☛✠☎✏✌✠✝✟ ☞✆✂✁☎☞ ✂✟✝ ✂☞ ✂ ☛☎✂☛☞✝✟✄☞
correlation analysis is robust to normality violations, ✂ ☛☎✂☛☞✝✟✄☞ ✁✝☛☛☎✂✂✌✠✝✟ ✆✂☞ ✁✝✟✝✏✁✌☎✝✁  n 
association was not found between simultaneous polysubstance use of cannabis and nicotine 
frequency and average frequency of acute adverse reactions, r(454) = .05, p = .326. Additionally, 
when controlling for social desirability via partial correlation, the relationship was still 
nonsignificant, rpartial(449) = .01, p = .789. 
 Average Distress Rating of Acute Adverse Reactions. The average distress rating of 
acute adverse reactions was normally distributed when examining a Normal Q-Q plot. However, 
cannabis and nicotine simultaneous polysubstance frequency was not normally distributed, but 




the distribution shape was similar to the average distress rating Normal Q-Q plot. An association 
was not discovered between simultaneous polysubstance use of cannabis and nicotine frequency 
and average distress rating of acute adverse reactions experienced when corrected with the 
Benjamini-Hochberg procedure, r(439) = .05, p = .034.  This finding remained nonsignificant 
when controlling for social desirability, rpartial (434) = .08, p = .084.  
Trait Positive Affect Associations 
 Hypothesis 2a.  
Total Acute Adverse Reactions. There was no correlation found between positive affect 
and total acute adverse reactions experienced, r(441) = -.09, p = .057. Further, a partial 
correlation was also performed to control for social desirability. After partialling out social 
desirability, the relationship between positive affect and total acute adverse reactions remained 
nonsignificant, rpartial(436) = .06, p = .201. 
 Average Frequency of Acute Adverse Reactions. Three outliers were detected via 
scatterplot. Similar to previous analyses discussed, the outliers were included in the analyses. 
The positive affect variable was normally distributed when examining a Normal Q-Q plot. 
However, the average frequency of acute adverse reactions experienced was not normally 
distributed, and although the distribution shape was not similar to the positive affect Normal Q-Q 
plot, ✂ ☛☎✂☛☞✝✟✄☞ ✁✝☛☛☎✂✂✌✠✝✟ ✂✟✂✂✍☞✠☞ ✠☞ ☛✝☎✏☞✌ ✌✝ ✟✝☛ ✂✂✠✌✍ ✡✠✝✂✂✌✠✝✟☞. There was no association 
found between positive affect and average frequency of acute adverse reactions experienced, 
r(443) = -.07, p = .148. Additionally, when controlling for social desirability via partial 
correlation, this relationship was still nonsignificant, rpartial(438) = .06, p = .224. 
 Average Distress Rating of Acute Adverse Reactions. Positive affect was not associated 
with average distress rating of acute adverse reactions experienced, r(428) = -.06, p = .257. This 




finding remained nonsignificant when controlling for social desirability, rpartial (423) = -.01, p = 
.862.  
Trait Negative Affect Associations 
 Hypothesis 2b.  
Total Acute Adverse Reactions. The total adverse reactions variable was normally 
distributed when examined using a Normal Q-Q plot. However, negative affect was not normally 
distributed, but the distribution shape was similar to the total acute adverse reactions Normal Q-
Q plot. There was a positive correlation between negative affect and total acute adverse reactions 
experienced, r(438) = .31, p < .001. Further, a partial correlation was also performed to control 
for social desirability. After partialling out social desirability, this positive relationship between 
negative affect and total acute adverse reactions remained significant, rpartial(433) = .20, p < 
.0005. 
 Average Frequency of Acute Adverse Reactions. Four outliers were detected via 
scatterplot. However, upon further examination of each case, and the large sample size, the 
outliers were included in the analyses. Both the average frequency of adverse reactions 
experienced, and negative affect variables were not normally distributed when examining a 
Normal Q-Q Plot. However, the distribution was similar in shape to each other. There was a 
positive correlation between negative affect and the average frequency of acute adverse reactions 
experienced, r(441) = .35, p < .001. Additionally, when controlling for social desirability via 
partial correlation, this significant positive relationship remained significant, rpartial(436) = .28, p 
< .0005. 
 Average Distress Rating of Acute Adverse Reactions. A positive correlation was found 
between negative affect and average distress rating of acute adverse reactions experienced, 




r(427) = .24, p < .001.  This positive association remained significant when controlling for social 
desirability, rpartial (422) = .22, p < .0005.  
Trait Positive Affect Predictions 
 Hypothesis 3a.  
Total Acute Adverse Reactions. The assumption of homoscedasticity was violated, in 
that the residual spread increased as the predicted values increased (i.e., increasing funnel-shaped 
distribution). Three outliers were detected (i.e., studentized deleted residuals greater than 3 
standard deviations), however, the outliers were valid (i.e., not due to data-entry errors) and were 
kept in the analyses. At the second block entry (i.☎✁✠ ✁ ✝✝☎✂ 2✄✞✠ the hierarchical multiple 
regression showed that the addition of positive affect did not show a significant change in R2 in 
predicting total acute adverse reactions, F(1,428) = 1.49, p = .223. Hierarchical multiple 
regression analyses done in this study were also conducted using social desirability scores as a 
control measure. The findings remained nonsignificant, F(1, 423) = 2.85, p = .092. See Table 6 
for a summary of the hierarchical multiple regression statistics for predicting total acute adverse 
reactions with positive affect as an added variable to the model. In addition, see Table 7 for 
simple correlations between all of the independent variables and each of the three outcome 











Table 6  
 
Hierarchical Multiple Regression Analysis for Trait Positive Affect Predicting Total Acute 
Adverse Reactions to Cannabis 
Dependent: Total Acute Adverse Reactions B SE B ✂ R2 R2adj p 
Model 1 (covariates)    .04 .04 < .0005 
 Constant 9.55 .63     
 Age -.08 .02 -.18    
 Gender -.65 .44 -.07    
 Cannabis Use Frequency < .0005 .01 <.01    
Model 2 (variables)    .05 .04 .223a 
 Constant 10.29 .87     
 Age -.07 .02 -.17    
 Gender -.66 .44 -.07    
 Cannabis Use Frequency < .0005 .01 <.01    
 Trait Positive Affect -.03 .02 -.06    
a




Pearson Correlation Coefficients Between Independent Variables and Acute Adverse 
Reactions to Cannabis in Hierarchical Multiple Regression Analyses 
  Dependent Variable 
Independent Variable  Total Acute 
Adverse Reactions 
Average Frequency 
of Acute Adverse 
Reactions 
Average Distress 
Rating of Acute 
Adverse Reactions 
Age  -.20* -.25* -.18* 
Cannabis Use Frequencya  -.04 -.34* -.30* 
Positive Affect  -.09 -.07 -.06 
Negative Affect  .31* .35* .24* 
a
Number of days for using cannabis in the last 3 months (i.e., 12 weeks) 
*
p < .01 
 
Average Frequency of Acute Adverse Reactions. The assumption of homoscedasticity 
was violated (i.e., increasing funnel-shaped distribution). Six outliers were detected (i.e., 
studentized deleted residuals greater than 3 standard deviations), however, the outliers were valid 
(i.e., not due to data-entry errors) and were kept in the analyses. At the second block entry (i.e., 
✁ ✝✝☎✂ ✟✄✞✠ ✌✆☎ ✆✠☎☛✂☛✁✆✠✁✂✂  ✏✂✌✠✁✂☎ ☛☎✞☛☎☞☞✠✝✟ ☞✆✝✆☎✝ ✌✆✂✌ ✁✝☞✠✌✠✡☎ ✂  ☎✁✌ did not show a 
significant change in R2 in predicting average frequency of acute adverse reactions, F(1,429) = 




.47, p = .493. See Table 8 for a summary of the hierarchical multiple regression statistics for 
predicting the average frequency of acute adverse reactions experienced with positive affect as 
an added variable to the model. However, after controlling for socially desirable responses, the 
addition of positive affect did reveal a significant change in R2, F(1,424) = 4.72, p = .030. 
Table 8  
 
Hierarchical Multiple Regression Analysis for Trait Positive Affect Predicting Average 
Frequency of Acute Adverse Reactions to Cannabis 
Dependent: Average Frequency of Acute 
Adverse Reactions 
B SE B ✂ R2 R2adj p 
Model 1 (covariates)    .17 .17 < .0005 
 Constant 16.16 1.25     
 Age -.15 .04 -.16    
 Gender -2.56 .89 -.13    
 Cannabis Use Frequency -.07 .01 -.29    
Model 2 (variable)    .18 .17 .493a 
 Constant 16.99 1.75     
 Age -.146 .04 -.16    
 Gender -2.57 .89 -.13    
 Cannabis Use Frequency -.07 .01 -.29    
 Trait Positive Affect -.03 .05 .05    
a
Value for change in R2 when adding Trait PA to model       
 
 Average Distress Rating of Acute Adverse Reactions. The assumption of 
homoscedasticity was violated, in that the residual spread increased as the predicted values 
increased (i.e., increasing funnel-shaped distribution). One outlier was detected (i.e., studentized 
deleted residuals greater than 3 standard deviations), however, the outliers were valid and were 
✄☎✁✌ ✠✟ ✌✆☎ ✂✟✂✂✍☞☎☞✁  ✌ ✌✆☎ ☞☎✁✝✟✝ ☎✂✝✁✄ ☎✟✌☛✍ ✟✠✁☎✁✠ ✁ ✝✝☎✂ ✟✄✞✠ ✌✆☎ ✆✠☎☛✂☛✁✆✠✁✂✂  ✏✂✌✠✁✂☎
regression showed that positive affect did not show a significant change in R2 in predicting the 
average distress rating of acute adverse reactions experienced, F(1,414) = .42, p = .516. This 
finding remained nonsignificant when controlling for social desirability, F(1,409) = .11, p = 
.745. Refer to Table 9 for a summary of the hierarchical multiple regression statistics for 




predicting the average distress rating of acute adverse reactions experienced with positive affect 
as an added variable to the model. 
Table 9  
 
Hierarchical Multiple Regression Analysis for Trait Positive Affect Predicting Average 
Distress Rating of Acute Adverse Reactions to Cannabis 
Dependent: Average Distress Rating of 
Acute Adverse Reactions 
B SE B ✂ R2 R2adj p 
Model 1 (covariates)    .14 .13 < .0005 
 Constant 1.78 .12     
 Age -.01 <.01 -.09    
 Gender -.27 .09 -.15    
 Cannabis Use Frequency -.01 <.01 -.26    
Model 2 (variable)    .14 .13 .516a 
 Constant 1.85 .17     
 Age -.01 <.01 -.09    
 Gender -.27 .09 -.15    
 Cannabis Use Frequency -.01 <.01 -.26    
 Trait Positive Affect <.01 .01 -.03    
aValue for change in R2 when adding Trait PA to model       
 
Trait Negative Affect Predictions 
 Hypothesis 3b.  
Total Acute Adverse Reactions. Two outliers were detected (i.e., studentized deleted 
residuals greater than 3 standard deviations), however, the outliers were valid and were kept in 
✌✆☎ ✂✟✂✂✍☞☎☞✁  ✌ ✌✆☎ ☞☎✁✝✟✝ ☎✂✝✁✄ ☎✟✌☛✍ ✟✠✁☎✁✠ ✁ ✝✝☎✂ ✟✄✞✠ ✌✆☎ ✆✠☎☛✂☛✁✆✠✁✂✂  ✏✂✌✠✁✂☎ ☛☎✞☛☎☞☞✠✝✟
showed that negative affect did indicate a significant change in R2 in predicting total acute 
adverse reactions, F(1,425) = 29.73, p < .001. The variance explained increased by 6.2% with 
the addition of trait negative affect to the model. There was still a significant change in R2 after 
controlling for social desirability, F(1,420) = 10.14, p = .002. See Table 10 for a summary of the 
hierarchical multiple regression statistics for predicting total acute adverse reactions with 
negative affect as an added variable to the model. 




Table 10  
 
Hierarchical Multiple Regression Analysis for Trait Negative Affect Predicting Total Acute 
Adverse Reactions to Cannabis 
Dependent: Total Acute Adverse Reactions B SE B ✂ R2 R2adj p 
Model 1 (covariates)    .05 .04 < .0005 
 Constant 9.55 .63     
 Age -.08 .02 -.18    
 Gender -.69 .44 -.08    
 Cannabis Use Frequency < .0005 .01 <.01    
Model 2 (variable)    .11 .10 < .0005a 
 Constant 5.90 .90     
 Age -.05 .02 -.13    
 Gender -.30 .43 -.03    
 Cannabis Use Frequency <.0005 .01 .01    
 Trait Negative Affect .14 .03 .26    
a
Value for change in R2 when adding Trait NA to model       
 
Average Frequency of Acute Adverse Reactions. The assumption of homoscedasticity 
was violated. Five outliers were detected (i.e., studentized deleted residuals greater than 3 
standard deviations), though, the outliers were valid (i.e., not due to data-entry errors) and were 
✄☎✁✌ ✠✟ ✌✆☎ ✂✟✂✂✍☞☎☞✁  ✌ ✌✆☎ ☞☎✁✝✟✝ ☎✂✝✁✄ ☎✟✌☛✍ ✟✠✁☎✁✠ ✁ ✝✝☎✂ ✟✄✞✠ ✌✆☎ ✆✠☎☛✂☛✁✆✠cal multiple 
regression showed that negative affect did show a significant change in R2 in predicting average 
frequency of acute adverse reactions experienced, F(1,427) = 36.05, p < .001. The variance 
explained increased by 6.4% with the addition of trait negative affect to the model. Therefore 
model 2, which included the addition of trait negative affect, explained 23% of the variation in 
average frequency acute adverse reactions to cannabis. After controlling for social desirability, a 
significant change in R2 remained, F(1,420) = 10.14, p = .002. See Table 11 for a summary of the 
hierarchical multiple regression statistics for predicting the average frequency of acute adverse 
reactions with negative affect as an added variable to the model. 
 
 




Table 11  
 
Hierarchical Multiple Regression Analysis for Trait Negative Affect Predicting Average 
Frequency Acute Adverse Reactions to Cannabis 
Dependent: Average Frequency of Acute 
Adverse Reactions 
B SE B ✂ R2 R2adj p 
Model 1 (covariates)    .17 .17 < .0005 
 Constant 15.99 1.25     
 Age -.15 .04 -.16    
 Gender -2.59 .87 -.14    
 Cannabis Use Frequency -.07 .01 -.29    
Model 2 (variables)    .24 .23 < .0005a 
 Constant 8.05 1.79     
 Age -.10 .04 -.11    
 Gender -1.76 .85 -.09    
 Cannabis Use Frequency -.07 .01 -.28    
 Trait Negative Affect .31 .05 .27    
a
Value for change in R2 when adding Trait NA to model       
 
Average Distress Rating of Acute Adverse Reactions. The assumption of 
homoscedasticity was violated (i.e., increasing funnel-shaped distribution). One outlier was 
detected (i.e., studentized deleted residuals greater than 3 standard deviations), however, the 
outlier was valid (i.e., not due to data-entry errors) and was kept in the analysis. At the second 
block entry (i.e✁✠ ✁ ✝✝☎✂ ✟✄✞✠ ✌✆☎ ✆✠☎☛✂☛✁✆✠✁✂✂  ✏✂✌✠✁✂☎ ☛☎✞☛☎☞☞✠✝✟ ☞✆✝✆☎✝ ✌✆✂✌ negative affect did 
reveal a significant change in R2 in predicting the average distress rating of acute adverse 
reactions experienced, F(1,413) = 10.38, p = .001. The variance explained increased by 2.1% 
with the addition of trait negative affect to the model. There was still a significant change in R2 
after controlling for social desirability, F(1,408) = 5.96, p = .015. Refer to Table 12 for a 
summary of the hierarchical multiple regression statistics for predicting the average distress 
rating of acute adverse reactions with negative affect as an added variable to the model. 
 
 






Hierarchical Multiple Regression Analysis for Trait Negative Affect Predicting Average 
Distress Rating of Acute Adverse Reactions to Cannabis 
Dependent: Average Distress Rating of 
Acute Adverse Reactions 
B SE B ✂ R2 R2adj p 
Model 1 (covariates)    .14 .13 < .0005 
 Constant 1.76 .12     
 Age -.01 <.01 -.09    
 Gender -.29 .09 -.16    
 Cannabis Use Frequency -.01 <.01 -.26    
Model 2 (variable)    .16 .15 .001a 
 Constant 1.32 .18     
 Age -.01 <.01 -.06    
 Gender -.24 .09 -.14    
 Cannabis Use Frequency -.01 <.01 -.25    
 Trait Negative Affect .02 .01 .15    
a
Value for change in R2 when adding Trait NA to model       
 
Exploratory Hypotheses 
Body Weight Associations 
 Hypothesis 1a.  
Total Acute Adverse Reactions. Two outliers were detected via scatterplot. However, 
upon further examination for both cases (e.g., checking for data-entry errors), and the large 
sample size, the outliers were included in the analyses. A correlation was not found between 
body weight and total acute adverse reactions, r(447) = -.07, p = .133. After controlling for social 
desirability via partial correlation, the relationship between body weight and total acute adverse 
reactions remained nonsignificant, rpartial(442) = -.08, p = .085. 
 Average Frequency of Acute Adverse Reactions. Three outliers were detected via 
scatterplot. However, upon further examination for both cases (e.g., data-entry errors), and the 
large sample size, the outliers were included in the analyses. A small negative correlation was 
observed between body weight and average frequency of acute adverse reactions experienced, 




r(450) = -.11, p = .021. Additionally, when controlling for social desirability via partial 
correlation, this negative association remained significant, rpartial(436) = -.12, p = .010. 
 Average Distress Rating of Acute Adverse Reactions. Three outliers were detected via 
scatterplot. However, upon further examination for each case, and the large sample size, the 
outliers were included in the analyses. A small negative association was found between body 
weight and average distress rating of acute adverse reactions experienced, r(435) = -.14, p = 
.004. After controlling for social desirability, this relationship stayed negative and remained 
significant, rpartial(430) = -.15, p = .002. 
Body Mass Index Associations 
 Hypothesis 1b.  
Total Acute Adverse Reactions. One outlier was detected via scatterplot. Upon additional 
inspection of the case, and the large sample size, the outlier was included in the analysis. An 
association was not found between BMI and total acute adverse reactions, r(446) = -.05, p = 
.278. Analogous to exploratory hypothesis 1a, a partial correlation was also performed to control 
for social desirability. After partialling out social desirability, there was still no relationship 
between BMI and total acute adverse reactions, rpartial(446) = -.07, p = .146. 
 Average Frequency of Acute Adverse Reactions. Similar to above, upon further 
examination of the case, the outlier was included in the analysis. BMI was not correlated with 
average frequency of acute adverse reactions experienced, r(449) = -.05, p = .282. The 
relationship between BMI and average frequency of acute adverse reactions after partialling out 
social desirability remained nonsignificant, rpartial(444) = -.07, p = .147. 
 Average Distress Rating of Acute Adverse Reactions. One outlier was detected via 
scatterplot and was included in the analysis. BMI was not associated with average distress rating 




of acute adverse reactions experienced, r(434) = -.03, p = .520. This finding also remained 
nonsignificant when controlling for social desirability, rpartial(429) = -.04, p = .373. 
Discussion 
 The primary purpose of this study was to investigate how simultaneous polysubstance use 
of cannabis and trait affect were associated with acute adverse reactions to cannabis; specifically, 
on the total, average frequency, and average distress ratings of these acute adverse reactions. 
Additionally, an exploratory examination was conducted to determine if body weight and BMI 
were related to the three variables measuring acute adverse reactions to cannabis.  
Simultaneous Polysubstance Use and Acute Adverse Reactions to Cannabis 
Cannabis and Alcohol Comparisons and Associations 
 Hypothesis 1a was partially supported when statistically significant mean differences 
were found in the total acute adverse reaction scores, but not in the average frequencies or 
average distress ratings of acute adverse reactions when comparing participants that have 
consumed cannabis simultaneously with alcohol and participants who have never consumed 
cannabis simultaneously with alcohol. From our study, participants who engaged in simultaneous 
cannabis and alcohol use scored higher on total acute adverse reactions, meaning that consuming 
cannabis and alcohol on the same occasion increased the likelihood of experiencing more unique 
acute adverse reactions (e.g., anxiety and paranoia experiences versus only experiencing 
paranoia) than someone who consumed cannabis without alcohol in any one session. These 
findings are consistent with some previous studies where individuals who engage in SPU of 
cannabis and alcohol were more likely to have more unique negative acute adverse reactions to 
cannabis (Fernández-Calderón et al., 2020; Lipperman-Kreda et al., 2017; Manwell et al., 2019). 
These results are also comparable to an ecological momentary assessment study where SAM 




(i.e., simultaneous alcohol and marijuana) use was related to more violence (i.e., argument, 
injury, or physical fight) the morning after compared to using marijuana alone (Lipperman-
Kreda et al., 2017). Another study supporting these findings discovered that university students 
who participated in SAM use reported more substantial acute effects for symptoms such as 
clumsiness and difficulty concentrating than the young adults who consumed alcohol or 
marijuana only (Lee et al., 2017). These more prominent acute effects may be due to the 
synergistic effects (i.e., increase the effects of one or more drugs; Alsherbiny & Li, 2018) 
between cannabis and alcohol (Ramaekers et al., 2011). As both synergistic or additive effects 
have been observed to be positively associated with acute adverse reactions, these greater mean 
differences in total acute adverse reactions to cannabis may be the result of the synergistic (or 
potentially additive) effects from the simultaneous use of cannabis and alcohol (e.g., Chihuri et 
al., 2017; Meier & Hatsukami, 2016; Pape et al., 2009) 
However, hypothesis 1c was not supported; there was not a statistically significant 
positive correlation between SPU of cannabis and alcohol frequency (i.e., ✁frequency✄ 
representing the percentage of cannabis uses in which alcohol was also used) and acute adverse 
reactions to cannabis. Even though there was no positive relationship between SPU of cannabis 
and alcohol frequency and acute adverse reactions to cannabis, our results support some previous 
literature where neither synergistic nor additive effects occurred when simultaneously using 
THC and ethanol products (Ballard & de Wit, 2011). This decrease in acute effects overall has 
previously been proposed to be due to either THC lessening the acute effects from ethanol or 
decreasing the desire to consume more alcohol (e.g., Ballard & de Wit, 2011). 
 
 




Cannabis and Nicotine Comparisons and Associations 
Hypothesis 1b was not supported, and after controlling for socially desirable responding, 
our results either showed no association or was opposite to what we hypothesized (depending on 
the acute adverse reaction scale); participants who have never consumed nicotine simultaneously 
with cannabis experienced a higher frequency of acute adverse reactions than participants who 
have never consumed both products simultaneously. Similarly, hypothesis 1d was not supported, 
even after accounting for social desirability; no positive correlation was found between 
simultaneous polysubstance use of cannabis and nicotine frequency (i.e., ✁frequency✄ 
representing the percentage of cannabis uses in which nicotine was also used) and acute adverse 
reactions to cannabis.  
 Although past research has shown that nicotine increases the acute adverse effects of 
THC (Crummy et al., 2020; Manwell et al., 2019), ✝✏☛ ☞✌✏✝✍✄☞  ✠✟✝✠✟✞☞ (after controlling for 
socially desirable responses) revealed no relationships, or when we did uncover a connection, it 
was contrary to what we hypothesized; participants who engaged in cannabis and nicotine 
simultaneous use had lower mean scores on the average frequency of acute adverse reactions to 
cannabis compared to those that have never engaged in cannabis and nicotine simultaneous use. 
However, these findings support some emerging evidence on nicotine and cannabinoid 
combinations that discovered that prior nicotine use decreased locomotor sensitization to 
cannabinoids (i.e., preceding nicotine use decreased the behavioural response to the same dose of 
cannabinoid; Rigo et al., 2020) (Crummy et al., 2020). Also, and in parallel with our findings, 
Crummy and colleagues (2020) concluded that there was no change in locomotor sensitization to 
nicotine following cannabinoid use (i.e., preceding cannabinoid use did not change the 
behavioural response to the same dose of nicotine; Rigo et al., 2020) (Crummy et al., 2020). 




These sensitization relationships (and lack of) may offer a potential explanation as to why our 
sample of simultaneous cannabis and nicotine users had a lower frequency of experiencing 
adverse reactions, or why our two groups did not differ on the other acute adverse reaction 
scales. The likelihood of experiencing acute reactions, in general, is possibly influenced by the 
order in which the person uses cannabis and nicotine when engaging in SPU. 
Trait Affect and Acute Adverse Reactions to Cannabis 
Trait Positive Affect Associations and Predictions 
 Hypothesis 2a was also not supported; no significant negative correlation was found 
between positive affect and acute adverse reactions to cannabis. Hypothesis 3a was partially 
supported, although with small effect sizes; when factoring in the covariates, age, gender, 
cannabis consumption frequency, and social desirability, the addition of trait positive affect did 
explain a statistically greater amount of the variation in the average frequency of acute adverse 
reactions to cannabis, specifically. 
 As previous studies have found a positive association between PA and 5-HT (e.g., 
William et al., 2006) and a negative association between PA and cortisol (e.g., Hoyt et al., 2015), 
a chemical reaction may be occurring between the cannabinoids and 5-HT and cortisol that may 
be serving as a protective factor against acute adverse reactions. Additionally, we may not have 
found a significant negative correlation or larger effect size as the scale we used to measure acute 
reactions to cannabis was specific to typically perceived adverse reactions. However, had this 
study also examined acute positive reactions, we may have seen a positive association between 
positive affect and acute positive reactions to cannabis. To further explore this possibility, future 
studies should examine the relationship between positive affect and acute positive reactions to 




cannabis while simultaneously investigating the association between negative affect and acute 
negative reactions to cannabis. 
Trait Negative Affect Associations and Predictions 
 However, hypothesis 2b was supported; people with higher trait negative affect reported 
more acute adverse reactions to cannabis. In addition, hypothesis 3b was also supported; the 
addition of trait negative affect did explain a statistically greater amount of the variation in acute 
adverse reactions to cannabis.  
 Although our findings support our hypotheses, these findings are not consistent with 
some previous studies investigating the relationship between negative affect and acute adverse 
responses to cannabis. LaFrance et al. (2020) measured depression, anxiety, and stress, which 
they classified as their negative affect variables, using the Depression Anxiety Stress Scale-21 
(DASS-21). The researchers concluded that neither depression, anxiety, nor stress were 
significantly positively associated with acute adverse reactions to cannabis (LaFrance et al., 
2020). However, they speculated that this was because the timeframe of their independent 
variable, measured by DASS-21, assessed negative affect over the last week (LaFrance et al., 
2020). In contrast, their dependent variable, measured by ARS, wa☞ ✝✡☎☛ ✝✟☎✄☞ ✂✠ ☎✌✠ ☎ ✟✠✁☎✁✠
indefinite) (LaFrance et al., 2020). Fortunately, the PANAS scale used in this study to measure 
affect coincides with the timeframe of the ARS scale, so this is potentially why this study 
detected a relationship between negative affect, where some previous studies did not (e.g., 
LaFrance et al., 2020). 
 The effect of trait negative affect found in this study may be grounded in the set and 
setting theory, where the drug response, in this case, the cannabis response, is dependent on 
pharmacological or non-pharmacological influences like ✠✟✌☎✟✌✠✝✟ ✟✠✁☎✁✠ ✁☞☎✌✄✞ ✂✟✝ ☎✟✡✠☛✝✟ ☎✟✌




✟✠✁☎✁✠ ✁☞☎✌✌✠✟✞✄) (Hartogsohn, 2016; WHO, 2016). Similar to positive affect, earlier studies have 
found associations between NA and cortisol, specifically a positive link (e.g., Piazza et al., 2013) 
  people with higher NA scores also had higher blood cortisol levels. These higher cortisol levels 
may be stress-✠✟✝✏✁✠✟✞✠ ✌✆✏☞ ✁☛✝✡✠✝✠✟✞ ✂ ☞✌☛☎☞☞ ✏✂  ✠✟✝☞☎✌✠ ✝☛ ✁☞☎✌✄✠ ✆✆✠✂☎ ✁✝✟☞✏ ✠✟✞ ✁✂✟✟✂☎✠☞
which may increase the likelihood of experiencing acute adverse reactions to cannabis. For 
✠✟☞✌✂✟✁☎✠ ✠  ☞✝ ☎✝✟☎✄☞ ✠✟✌☎✟✌✠✝✟☞ ✆✆✠✂☎ ✁✝✟☞✏ ✠✟✞ ✁✂✟✟✂☎✠☞ ✂☛☎ negative (e.g., in a bad mindset), 
their experience with cannabis may also be negative (e.g., experiencing an acute adverse 
reaction). Therefore, if someone has high trait negative affect, a general tendency to respond 
negatively to their environment, this negative predisposition may increase their chances of 
experiencing acute adverse reactions to cannabis.  
Exploratory Hypotheses 
Body Weight and Body Mass Index and Acute Adverse Reactions to Cannabis 
 Exploratory hypothesis 1a was partially supported; a negative correlation was found 
between body weight and the average frequency of acute adverse reactions experienced. Another 
negative association was also found between body weight and average distress of acute adverse 
reactions experienced; however, this negative association was not found for the total acute 
adverse reactions experienced. Exploratory hypothesis 1b was not supported; no significant 
negative correlation was found between BMI and cannabis acute adverse reactions. 
 Although BMI was not associated with any of the three facets of cannabis acute adverse 
reactions measured here, body weight had a small negative correlation with the average 
frequency and the average distress rating of the acute adverse responses experienced. A possible 
explanation for this negative association between body weight and acute adverse reactions to 
cannabis is the dose in relation to body weight. It may be that the lower the absolute body 




weight, the more likely someone will over-consume cannabis for their weight. Previous studies 
have shown that the higher the quantity of cannabis consumed increases the likelihood of 
experiencing acute adverse effects, especially with cannabis products containing a greater 
amount of THC (e.g., Hunault et al., 2009). Therefore, the susceptibility to cannabis acute 
adverse reactions may increase as body weight decreases due to a lower physiological tolerance 
per unit of cannabis and less body fat within which the cannabis can remain inactive.  
 Limitations  
 Nevertheless, the conclusions from this study should be evaluated along with the 
limitations. As this was a retrospective cross-sectional design, participants may not accurately 
remember their past experiences with cannabis use. In addition to their recall accuracy, we do 
not know how far back in time they are reflecting and thus reporting. That is, some participants 
may have been reporting incidents that occurred within the last few days, while others may have 
been reporting events that occurred months or years ago. Future research should incorporate 
longitudinal study designs to limit recall and timeframe reporting errors. Additionally, 
statistically significant results found in this study were often associated with low effect sizes 
(e.g., mean differences, correlations, proportion of variances), which can occur when analyzing 
large sample sizes. Another limitation of this study revolves around measuring cannabis dose, 
especially concerning retrospective studies, as the amount of cannabis consumed is associated 
with acute effects (WHO, 2016). Furthermore, many participants are often inaccurate at 
reporting the types of cannabinoids in their cannabis products and the quantity of which they 
consume them. Because of these issues, we could not incorporate cannabis dose as a covariate in 
our analyses. Studies of the typical amounts of THC and other cannabinoids in commonly used 




cannabis preparations should be priorities for future retrospective research on the short-term 
health effects of cannabis.  
For our exploratory hypotheses, self-reported BMI was being used as an indirect measure 
of body fat percentage (Yu et al., 2013), and in-laboratory BMI assessments, or other more direct 
methods of BFP estimation should be used in future studies, such as skinfold calliper 
measurements or dual-energy X-ray absorptiometry (DEXA) (Harvard, 2020). Also, the design 
of this study was cross-sectional. Therefore, the associations and predictions found between 
simultaneous polysubstance use, trait affect, and body composition cannot be attributed as a 
cause of acute adverse experiences due to cannabis use.  
Implications  
 Investigating the association between SPU, trait affect, body composition, and acute 
adverse reactions to cannabis has implications for cannabis users, prescribing physicians, nurse 
practitioners, and public health educators. As non-medicinal cannabis use in Canada has been 
legalized since 2018, there may be an increase in people interested in trying cannabis for the first 
time, and they should be aware of their vulnerability to experiencing these acute adverse 
reactions. Additionally, physicians and practitioners prescribing medicinal cannabis should be 
mindful ✝  ✌✆☎✠☛ ✁✂✌✠☎✟✌☞✄ susceptibility to these acute adverse reactions. Therefore, these 
findings, in particular the trait NA findings, may aid those who are inexperienced with cannabis 
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1 What is your age? __________ years old (numerical) 
2 What was your 
biological sex at birth? 
1. Female 
2. Male 
3. I do not identify with the options listed 
4. Prefer not to say 




5. I do not identify with the options listed 
6. Prefer not to say 




3. Caucasian (White) 
4. Hispanic/Latino/Latina/Latinx 
5. Indigenous (First Nations, Métis, or Inuit) 
6. Middle Eastern 
7. I do not identify with the options listed 
8. Prefer not to say 
5 What is your sexual 
orientation? 
1. Exclusively heterosexual 
2. Predominantly heterosexual, only incidentally 
homosexual 
3. Predominately heterosexual, but more than incidentally 
homosexual 
4. Equally heterosexual and homosexual 
5. Predominately homosexual, but more than incidentally 
heterosexual 
6. Predominately homosexual, only incidentally 
heterosexual 
7. Exclusively homosexual 
8. No socio-sexual contacts or reactions (asexual) 
9. I do not identify with the options listed. 
10. Prefer not to say 




12. Canadian with multiple citizenship. 
13. None of the above. Please specify country/countries: 
_______________ 
7 What country do you 
currently live in? 
1. Canada  
2. Not in Canada. Please specify country: 
_______________ 




8 What country did you 
spend most of your life 
in? 
1. Canada 
2. Not in Canada. Please specify country: 
_______________ 
9 What is the highest level 
of education you have 
completed? 
1. None 
2. Elementary School 
3. Some High School 
4. High School Completed 
5. Some College or Technical 
6. College Completed 
7. Some Undergraduate  
8. Undergraduate Degree Completed 
9. Some Post Graduate 
10. Completed Post Graduate 
10 What is your 
work/employment 
status? 
1. Employed full-time 
2. Employed part-time 
3. Unemployed 
11 Are you currently a 
student at a university or 
college? 
1. Yes   full time 
2. Yes   part time 
3. No 
12 What is your marital 
status?  
1. Common-Law 
2. In a committed relationship (not married or common-
law) 
3. Married 
4. Separated or Divorced 
5. Single 
6. Widowed  
13 What is your religious 
affiliation? 
1. Buddhist  
2. Catholic 
3. Christian 




8. Protestant  
9. Sikh 
10. No religious affiliation  
11. None of these 
14 What is the strength of 
your religious beliefs? 
1. Not applicable (no religious affiliation) 
2. Not strong at all 
3. Not very strong 
4. Somewhat strong 
5. Very strong 
6. Extremely strong 
15 Which unit of height 
would you prefer to 
1. Centimeter (cm) 
2. Feet (ft) and inches (in) 




report with for your 
height? 
16 What is your height in 
centimeters (cm)? 
1. ____________ (cm) (numerical) 
17 What is your height in 
feet and inches?  
For example, if you are 
5 feet and 4 inches, 
 ✁✆✂✄☎ ✆✝✞  
1. ______ (ft)(in) (numerical) 
18 Which unit of weight 
would you prefer to 
report with for your 
weight? 
1. Kilogram (kg) 
2. Pound (lb) 
19 How much do you 
weight in kilograms 
(kgs)? 
1. ____________ (kg) (numerical) 
20 How much do you 
weight in pounds (lbs)? 




















The Cannabis Reason, Age, Frequency, Type, and Setting Questionnaire (CRAFTS-Q) 
Instructions: Please read the definition for Cannabis provided below. Additionally, some 
examples of common Cannabis terminology and products have been provided along with 
the definition.  
 
Term Definition 
Cannabis (e.g., marijuana, weed, pot, 
hash/hashish, THC, CBD) 
Refers to the generic name for drugs or 
compounds that come from plants 





1 Have you read the definition for Cannabis 
stated above? (If not, please read the 
definition for Cannabis and then continue to 
the remaining questions) 
1. Yes, and I understand the definition 
for Cannabis stated above. 
2. Yes, but I did not understand the 
definition for Cannabis stated 
above. 
3. No, I have not read the definition 
for Cannabis stated above. 
2 Have you ever consumed cannabis 




3 How old were you when you consumed 
cannabis for the first time? 
1. ______ years old (numerical) 
4 Do you currently consume any cannabis 




5 Have/Do you consider(ed) yourself to be a 
regular cannabis user? 
0. No 
1. Yes 
6 What cannabinoids (e.g., THC, CBD) 
have you consumed in your cannabis 
products in your lifetime? Please select all 
that apply. 
2. THC (Tetrahydrocannabinol)  
3. CBD (Cannabidiol)  
4. Other: Please specify _______ 
5. Unsure 
7 What cannabinoid (e.g., THC, CBD) 
profiles have you consumed in your 
cannabis products in your lifetime from the 




1. THC (Tetrahydrocannabinol) 
dominant cannabis product (e.g., 
 ✁✂✄☎ ✆✁✝✞✟ (i.e., a higher 
percentage of THC than CBD)  
2. CBD (Cannabidiol) dominant 
cannabis product (e.g.,  High 
✝✠✡✞✟ (i.e., a higher percentage of 
CBD than THC) 




3. A balanced cannabis product of 
THC and CBD (e.g., "Balanced 
1:1") (i.e., similar percentage of 
both THC and CBD) 
4. Unsure 
8 What cannabinoid (e.g., THC, CBD) 
profile have/do you consume(d) in your 
cannabis products most of the time from the 
below options? Please select one option 
only. 
1. THC (Tetrahydrocannabinol) 
dominant cannabis product (e.g., 
 ✁✂✄☎ ✆✁✝✞✟ (i.e., a higher 
percentage of THC than CBD)  
2. CBD (Cannabidiol) dominant 
cannabis product (e.g., High 
✝✠✡✞✟ (i.e., a higher percentage of 
CBD than THC) 
3. A balanced cannabis product of 
THC and CBD (e.g., "Balanced 
1:1") (i.e., similar percentage of 
both THC and CBD) 
4. Unsure 
9 What method(s) have you used to consume 
cannabis? Please select all that apply. 
1. Capsules (e.g., pills, liquid gels) 
2. Dabbing (e.g., dab rig, dab pen) 
3. Edibles (e.g., brownies) 
4. Smoking (e.g., joint, pipe, bong, 
hookah) 
5. Tinctures (e.g., liquid extract 
dropped under tongue) 
6. Topicals (e.g., creams) 
7. Vaping (i.e., using a vaporizer) 
(e.g., vape pen, dry herb vaporizer) 
10 What method did/do you use most of the 
time to consume cannabis? 
1. Capsules (e.g., pills, liquid gels) 
2. Dabbing (e.g., dab rig, dab pen) 
3. Edibles (e.g., brownies) 
4. Smoking (e.g., joint, pipe, bong, 
hookah) 
5. Tinctures (e.g., liquid extract 
dropped under tongue) 
6. Topicals (e.g., creams) 
7. Vaping (i.e., using a vaporizer) 
(e.g., vape pen, dry herb vaporizer) 
11 For what purposes(s) did/do you consume 
cannabis most of the time? 
1. Mainly/always for 
medicinal/therapeutic (i.e., 
lessening symptoms and/or treating 
disease; self-prescribed or 
prescribed by a physician) purposes 
2. Mainly/always for non-
medicinal/recreational purposes 








12 What purpose(s) did/do you consume 
cannabis for in your lifetime? 
1. Only for medicinal/therapeutic (i.e., 
lessening symptoms and/or treating 
disease; self-prescribed or 
prescribed by a physician) purposes  
2. Only for non-medicinal/recreational 
purposes 
3. Both medicinal/therapeutic and 
non-medicinal/recreational 
purposes 
13 If you did consume cannabis for 
medicinal/therapeutic (i.e., lessening 
symptoms and/or treating disease) purposes, 
is it self-prescribed or prescribed by a 
physician? 
1. Self-prescribed (i.e., not 
prescribed by a physician) 
2. Prescribed by a physician (e.g., 
family doctor) 
3. Both. Self-prescribe and 
prescribed by a physician. For 
example, I self-prescribe cannabis 
to help me fall asleep, and I have 
prescription from a physician for 
cannabis to alleviate my anxiety. 
14 What condition(s) led you to seek out 
cannabis for medicinal/therapeutic purposes 
(i.e., what is it self-prescribed/prescribed 
for)? Please select all that apply.  
1. Anxiety 
2. Post-traumatic stress disorder 
(PTSD) 
3. Chronic pain 
4. Depression 
5. Stress  
6. Epilepsy 
7. Insomnia (i.e., a sleep disorder 
characterized by sleeplessness) 
8. Headaches 
9. Nightmares 
10. Appetite  
11. Muscle spasms  
12. Nausea 
13. Other: Please specify: __________ 
15 In the last week (i.e., 7 days) from today, 
how many days did you consume cannabis?  
For example, if today is Friday, how many 
days out of the week did you consume 
cannabis from last Friday? 
________ day(s) in the last week 
(numerical) 
16 In the last month (i.e., 4 weeks) from 
today, how many days did you consume 
cannabis? 
________ day(s) in the last month 
(numerical) 




For example, if today is March 1st, how 
many days did you consume cannabis from 
February 1st? 
17 In the last 3 months (i.e., 12 weeks) from 
today, how many days did you consume 
cannabis? 
For example, if today is July 1st, how many 
days did you consume cannabis from April 
1st? 
________ day(s) in the last 3 months 
(numerical) 
18 When you have consumed cannabis, how 
many people were you around (regardless if 
they are consuming cannabis or not), most 
of the time? 
0. Not applicable (i.e., I mostly or 
have only ever consumed cannabis 
by myself when no one else is 
around) 
1. With one other person 
2. With two other people 
3. With three other people 
4. With four other people 
5. With five other people 
6. With six or more people 
19 When you have consumed cannabis, how 
many of the people around you were ALSO 
consuming cannabis, most of the time? 
0. Not applicable (i.e., I mostly or 
have only ever consumed cannabis 
by myself when no one else is 
around) 
1. None of the people around me are 
consuming cannabis 
2. Less than half of the people 
around me are consuming 
cannabis 
3. Half of the people around me are 
consuming cannabis when I am 
also consuming cannabis 
4. More than half of the people 
around me are consuming 
cannabis when I am also 
consuming cannabis 
5. All of the people around me are 
consuming cannabis when I am 
also consuming cannabis 
20 What environment did/do you consume 
cannabis in most of the time?  
 
1. Inside my own home/apartment 
2. ✡✟☞✠✝☎ ☞✝ ☎✝✟☎ ☎✂☞☎✄☞
home/apartment 
3. Outside in non-public space (e.g., 
private backyard) 
4. Outside in public space (e.g., public 
park, public hiking trails) 
5. At work 






8. Cannabis lounge/cafe 
9. Other. Please specify: __________ 
21 What environment were/are you 
experiencing the effects of cannabis in most 
of the time?  
 
1. Inside my own home/apartment 
2. ✡✟☞✠✝☎ ☞✝ ☎✝✟☎ ☎✂☞☎✄☞
home/apartment 
3. Outside in non-public space (e.g., 
private backyard) 
4. Outside in public space (e.g., public 
park, public hiking trails) 
5. At work 
6. School 
7. Bars/Nightclub 
8. Cannabis lounge/cafe 





















Simultaneous Polysubstance Use   Cannabis, Alcohol and Nicotine Questionnaire (SPU-CAN) 
Instructions: Please read the definition for Cannabis provided below. Additionally, some 
examples of common Cannabis terminology and products have been provided along with 
the definition.  
 
Term Definition 
Cannabis (e.g., marijuana, weed, pot, 
hash/hashish, THC/CBD) 
Refers to the generic name for drugs or 
compounds that come from plants 





1 Have you ever used cannabis in your 
lifetime? 
 
Skip logic 1:  ✁ ✂✄✄✝  ✆✝ ✂✄✝ ✄✁✄☎ ✆✄
✆✝✞ ✟✂✁✂✆✠✆✟✂✄✂ ✡☛✄✝ ✂☛ ✆☞✞  ✁ ✂✌☛ 
is answered in Q1, participant skips 
to end of SPU-CAN questionnaire 
0. No 
1. Yes 
2 Have you ever consumed alcohol in 
your lifetime? 
 
Skip logic 1: If ✂✄✄✝  is answered in 
Q2, participant goes to Q3. If ✂✌☛  
is answered in Q2, participant skips 
to Q5.  
0. No 
1. Yes 
3 Have you every consumed alcohol 
simultaneously with cannabis (i.e., 
administering alcohol and cannabis 
on the same occasion)? 
 
Skip logic 1:  ✁ ✂✄✄✝  ✆✝ ✂✄✝ ✄✁✄☎ ✆✄
Q3, participant goes to Q4✞  ✁ ✂✌☛ 




4 When you use(d) cannabis, what 
percentage of those times on average 
do/did you simultaneously consume 
alcohol (i.e., consuming alcohol and 
cannabis on the same occasion)? 
_________ % (numerical) 




For example, if you consumed 
cannabis on average 4 times a week, 
and on average simultaneously 
consumed alcohol 1 of those times, 
your answer would be the following: 
25 %. 
5 Have you ever used nicotine (e.g., 
cigarettes, cigars, etc.) in your 
lifetime? 
 
Skip logic 1: If ✂✄✄✝  is answered in 
Q5, participant goes to Q6. If ✂✌☛  




6 Have you ever used nicotine 
simultaneously with cannabis (i.e., 
administering nicotine and cannabis 
on the same occasion)? 
 
Skip logic 1:  ✁ ✂✄✄✝  ✆✝ ✂✄✝ ✄✁✄☎ ✆✄
Q6, participant goes to Q7✞  ✁ ✂✌☛ 




7 When you use(d) cannabis, what 
percentage of those times on average 
do/did you simultaneously consume 
nicotine (i.e., consuming nicotine 
and cannabis on the same 
occasion)? 
For example, if you consumed 
cannabis on average 4 times a week, 
and on average simultaneously 
consumed nicotine 1 of those times, 
your answer would be the following: 
25 %. 












Adverse Reactions Scale  
Instructions: We are interested in whether you have experienced any of the following 
adverse reactions to acute cannabis intoxication. When providing your answers please only 





1 Anxiety Yes/No 
2 Panic Attack Yes/No 
3 Feeling out of control Yes/No 
4 Migraine/Headache Yes/No 
5 Vomiting Yes/No 
6 Nausea Yes/No 
7 Cold Sweats Yes/No 
8 Hot Flash Yes/No 
9 Tunnel Vision Yes/No 
10 Dizzy Yes/No 
11 Light headed/head rush   Yes/No 
12* Off balance/unsteady    Yes/No 
13 Seeing black spots   Yes/No 
14 Fainting/passing out Yes/No 
15 Racing heart   Yes/No 
16 Heart palpitations/arrhythmia Yes/No 
17 Chest/lung discomfort Yes/No 
18 Trouble breathing Yes/No 
19 Coughing fit  Yes/No 
20 Paranoia Yes/No 
21 Auditory hallucinations  Yes/No 
22 Visual hallucinations Yes/No 
23 Other hallucinations Yes/No 
24 Dissociation (i.e. feeling disconnected from self or reality)   Yes/No 
25* Numbness  Yes/No 
26* Feelings of body humming or vibrating Yes/No 
27** Cutaneous (i.e., skin) sensitivity Yes/No 
28** Misophonia (i.e., negative reaction(s) to specific common 
sound(s)) 
Yes/No 
29** Hyperosmia (i.e., enhanced smelling abilities) Yes/No 




Display these questions for any symptoms for which [Yes] is selected above:   
# Question Response Format 
1 Approximately what percentage of the time that you use 
cannabis do you experience [symptom name (e.g. 
Anxiety)]?  
___________ % (numerical) 
2 On average, how distressing was experiencing ______ 
[symptom name (e.g. Anxiety)] while under the influence 
of cannabis? 
0 = Not at all distressing 
1 = Mildly distressing 
2 = Moderately distressing 
3 = Quite distressing  
4 = Severely distressing 
 
*Authors of this scale have suggested that these items may be taken out for future research 
studies.  
** Exploratory adverse reacti✝✟☞ ✂✝✝☎✝ ✂✟✝ ✟✝✌  ☛✝  ✌✆☎ ✝☛✠✞✠✟✂✂ ✁ ✝✡☎☛☞☎ ✡☎✂✁✌✠✝✟☞ ✎✁✂✂☎✄✁ 





















Positive and Negative Affect Schedule 





1 Enthusiastic 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
2 Interested 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
3 Determined 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
4 Excited 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
5 Inspired 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
6 Alert 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
7 Active 1. Very slightly or not at all 
2. A little 
3. Moderately 




4. Quite a bit 
5. Extremely 
8 Strong 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
9 Proud 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
10 Attentive 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
11 Scared 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
12 Afraid 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
13 Upset 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
14 Distressed 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
15 Jittery 1. Very slightly or not at all 




2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
16 Nervous 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
17 Ashamed 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
18 Guilty 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
19 Irritable 1. Very slightly or not at all 
2. A little 
3. Moderately 
4. Quite a bit 
5. Extremely 
20 Hostile 1. Very slightly or not at all 
2. A little 
3. Moderately 













Desirability Scale   Personality Research Form 
Read each statement and decide whether or not it describes you. If you agree with the statement 
or decide that it does describe you, answer TRUE. If you disagree with a statement or feel that it 
is not descriptive of you, answer FALSE. Answer every item either true or false, even if you are 





1 I am quite able to make correct decisions on difficult questions. 0. False 
1. True 
2 I am never able to do things as well as I should. 0. False 
1. True 
3 My life is full of interesting activities. 0. False 
1. True 
4 I believe people tell lies any time it is to their advantage. 0. False 
1. True 
5 If someone gave me too much change, I would tell him. 0. False 
1. True 
6 I would be willing to do something a little unfair to get something 
that was important to me. 
0. False 
1. True 
7 I get along with people at parties quite well. 0. False 
1. True 
8 I did many very bad things as a child. 0. False 
1. True 
9 I am glad I grew up the way I did. 0. False 
1. True 
10 I often question whether life is worthwhile. 0. False 
1. True 
11 I am always prepared to do what is expected of me. 0. False 
1. True 
12 My daily life includes many activities I dislike. 0. False 
1. True 




14 Many things make me feel uneasy. 0. False 
1. True 
15 I am careful to plan for my distant goals. 0. False 
1. True 









 Infrequency Scale   Personality Research Form  
Read each statement and decide whether or not it describes you. If you agree with the statement 
or decide that it does describe you, answer TRUE. If you disagree with a statement or feel that it 
is not descriptive of you, answer FALSE. Answer every item either true or false, even if you are 





1 I have never bought anything in a store. 0. False 
1. True 
2 I could easily count from one to twenty-five. 0. False 
1. True 
3 I can run a mile (1.6 km) in less than four minutes. 0. False 
1. True 
4 I have never talked to anyone by telephone. 0. False 
1. True 




6 I make all my own clothes and shoes. 0. False 
1. True 
7 I have never brushed or cleaned my teeth. 0. False 
1. True 
8 Things with sugar in them usually taste sweet to me. 0. False 
1. True 
9 Sometimes I see cars near my home. 0. False 
1. True 
10 I have never had any hair on my head. 0. False 
1. True 
11 I have traveled away from my hometown. 0. False 
1. True 
12 I have never ridden in an automobile. 0. False 
1. True 
13 I have never felt sad. 0. False 
1. True 
14 I try to get at least some sleep every night. 0. False 
1. True 
15 Sometimes I feel thirsty or hungry. 0. False 
1. True 









Cannabis Use During COVID-19 Restrictions Information Questionnaire 
Term Definition 
Cannabis (e.g., marijuana, 
weed, THC, CBD) 
Refers to the generic name for drugs or compounds that come 
from plants belonging to the genus Cannabis. 
COVID-19 restrictions: Refers to a period of time of measures set in place (e.g., 
physical distancing, travel bans, closed borders, lockdowns, 
etc.) to restrict human contact because of the Coronavirus 
disease 2019 (COVID-19) disease which was upgraded to 






1 Have you experienced a lockdown, or other 
similar type of government-imposed restrictions, 
during the COVID-19 pandemic? 
 
Skip logic 1: If participant endorses ✂✌☛ ✞
participant skips to end of COVID-19 
Information Questionnaire. If participant 




2 During the COVID-19 restrictions, how would 
you describe the frequency (i.e., different 
sessions) of your cannabis consumption? 
 
Skip logic 1: If participant endorses Q2 (1), 
participant will be directed Q3 and will skip Q4. 
 
Skip logic 2: If participant endorses Q2 (2), 
participant will skip Q3 and be directed to Q4. 
 
Skip logic 3: If participant endorses Q2 (3), 
participant will skip Q3 & Q4 and be directed to 
Q5. 
1. I have decreased the 
frequency of my cannabis 
consumption during the 
COVID-19 restrictions. 
2. My cannabis consumption 
frequency has not changed 
during the COVID-19 
restrictions. 
3. I have increased the frequency 
of my cannabis consumption 
during the COVID-19 
restrictions. 
3 If the frequency of your cannabis consumption 
has increased during the COVID-19 restrictions, 
how often do you consume cannabis? 
1. Less than once a month 
2. Once a month 
3. Once a week  
4. Two or more times a week  
5. Once daily  
6. Multiple times daily 




4 If the frequency of your cannabis consumption 
has decreased during the COVID-19 
restrictions, how often do you consume 
cannabis? 
1. Less than once a month 
2. Once a month 
3. Once a week  
4. Two or more times a week  
5. Once daily  
6. Multiple times daily 
5 Have you consumed a cannabis product for the 
first time during the COVID-19 pandemic? 
0. No 
1. Yes 
6 During the COVID-19 restrictions, how would 
you describe your mental health overall? 
1. I have experienced a decline in 
my mental health overall 
during the COVID-19 
restrictions.  
2. My mental health overall has 
not changed during the 
COVID-19 restrictions. 
3. I have experienced an 
improvement in my mental 
health overall during the 




















Email to Lakehead University Professors and Students 
Hello [insert professor name here], 
  
My name is Shayna Cummings and I am currently recruiting volunteers to participate in 
my  ✂☞✌☎☛✄☞ ✌✆☎☞✠☞ project, The Cannabis Experiences Study (The CAN-E Study), conducted 
under the supervision of Dr. Mazmanian. 
  
We would greatly appreciate your willingness to send the following information to your students. 







Hello Undergraduate/Graduate Student, 
   
My name is Shayna Cummings and I am currently recruiting volunteers to participate in 
my  ✂☞✌☎☛✄☞ thesis project, The Cannabis Experiences Study (The CAN-E Study), conducted 
under the supervision of Dr. Mazmanian. 
  
The main purpose of this study is to examine ✠✟✝✠✡✠✝✏✂✂☞✄ short-term reactions to cannabis use.  
  
Format and Time Requirement: 
  Online survey 
  No more than 1 hour 
 
Compensation: 
  You may select one out of the following two options: 
1. Earn 1 bonus mark towards any psychology course accepting bonus credits. 
2. If you are ineligible or do not want a bonus mark, you may enter in a draw for a 
chance to win 1 out of 5 $20.00 electronic gift cards. If you enter into the draw 
and win, you will have the choice of either a Chapters or Boston Pizza electronic 
gift card. 
Eligibility: 
  Any sex or gender 
  18 years of age or older 
  Past/current cannabis user OR non-cannabis user (i.e., have never tried cannabis in 
your lifetime) 
  




If you are interested in participating and are a Lakehead University student taking at least 
one psychology course, click: https://lupsych.sona-systems.com/ to access 
our study through the Lakehead Sona System, under the project titled, The Cannabis 
Experiences Study   The CAN-E Study. 
 
If you have any further questions regarding this study, you may contact myself: 
 






















































Information Letter [General Public] 
Dear Potential Participant,  
 
 ✆✂✟✄ ✍✝✏  ✝☛ ✍✝✏☛ ✠✟✌☎☛☎☞✌ ✠✟ ✌✆☎ ✁ ✆☎ ✂✂✟✟✂☎✠☞  ✂✁☎☛✠☎✟✁☎☞ ✎✌✏✝✍✄ ✟ ✆☎ ✂  -E Study). This 
study is being conducted by Shayna Cummings, a MSc Psychological Science student, and is 
supervised by Dr. Dwight Mazmanian, a full-time faculty member in the Department of 
Psychology at Lakehead University. Your participation in this study will help us better 
understand the short-term effects of cannabis use. Before you decide to take part in this study, 
please carefully review the information below to understand what is involved.  
 
What is the purpose of the study?  
 
 ✆☎  ✂✠✟ ✁✏☛✁✝☞☎ ✝  ✌✆✠☞ ☞✌✏✝✍ ✠☞ ✌✝ ☎✂✂ ✠✟☎ ✁✂☛✌✠✁✠✁✂✟✌☞✄ ☞✆✝☛✌-term effects from cannabis. This 
study will ask questions about your cannabis experiences, but participants do NOT have to use 
cannabis to participate.  
 
How long will the study take to complete?  
 
This survey is not expected to last longer than 1 hour. It is online and hosted on the 
SurveyMonkey platform, so you may complete it at a time and location of your choosing. If you 
have any questions about this study, please contact the research team.  
 
Contact Information:  
 
If you would like to contact the research team, please send an email to the Student Investigator 
(Shayna Cummings) or the Principal Investigator (Dr. Dwight Mazmanian): 
  hhab.laboratory@gmail.com (Shayna Cummings, HBSc, MSc Psychological Science 
student) 
  dmazmani@lakeheadu.ca (Dwight Mazmanian, PhD, CPsych) 
 
Is the study anonymous?  
 
This study is anonymous. No identifying information will be collected. As no identifying 
information will be collected, no identifying information will be alongside or associated with any 
of the data, analyses, or methods of dissemination. For publication purposes, all survey 
information and responses will be securely stored at Lakehead University for five years. Please 
note, however, that the online survey tool used in the study (SurveyMonkey.com) is hosted by a 
server located in the USA. The US Patriot Act permits U.S. law enforcement officials, for the 
purpose of anti-terrorism investigation, to seek a court order that allows access to the personal 
☛☎✁✝☛✝☞ ✝  ✂✟✍ ✁☎☛☞✝✟ ✆✠✌✆✝✏✌ ✌✆☎ ✁☎☛☞✝✟✄☞ ✄✟✝✆✂☎✝✞☎✁ ✡✟ ✡✠☎✆ ✝  ✌✆✠☞ ✆☎ ✁✂✟✟✝✌ ✂☎☞✝✂✏✌☎✂✍
guarantee the full anonymity of your data. With your consent to participate in this study, you 
acknowledge this. 
 




Do I have the right to decline to answer any questions? 
 
Participants maintain the right to decline to answer any question(s). Your participation in this 
research is completely voluntary, and if you choose not to participate, you may do so without 
consequence or the need to explain why. You may also discontinue your participation at any time 
without explanation or penalty. Once you submit your data it cannot be withdrawn due to its 
anonymity. 
 
What will the survey be used for?  
 
Participant responses will be used for the thesis of the student investigator, Shayna Cummings. 
The study findings will also be used for research publications and/or presentations at 
conferences. Your identity will remain anonymous throughout these processes as well. 
Researchers who will have access to the data will be limited to Shayna Cummings (MSc 
Psychological Science Student), Casey Oliver (MA Clinical Psychology Student), Erika Puiras 
(MA Clinical Psychology Student), and Dr. Dwight Mazmanian. 
 
How can you benefit from this study?  
 
Potential benefits include participating in research that aims to help in better predicting some 
cannabis short-✌☎☛  ☛☎✂✁✌✠✝✟☞✁  ☞ ✂ ✁✌✆✂✟✄ ✍✝✏✄  ✝☛ ✁✂☛✌✠✁✠✁✂✌✠✟✞ ✠✟ ✌✆✠☞ ☛☎☞☎✂☛✁✆✠ ✍✝✏  ✂✍ ☎✟✌☎☛
into a draw to win one of ten $25 (CAD) electronic gift cards of your choosing (Indigo, Tim 
Hortons, or Walmart). If you enter into the draw to win the electronic gift card, you will be asked 
for your email address in order to be contacted and sent the electronic gift card should you win. 
This email address will not be associated with your responses.  
 
What are the risks of participating in this study?  
 
There are no known physical risks associated with participating. However, some of the material 
in the survey asks questions on sensitive subject matter that might result in some minor 
psychological discomfort for some people. If this occurs, please contact the Crisis Services 
Canada phoneline at 1-833-456-4566.  
 
Can I see the results?  
 
A summary of the research findings may also be available to you once the study is completed. 
Please note that it might take up to 1 year from the time of your participation before the study is 
completed and the findings are available. If you wish to receive a summary of the findings, 
please provide your email address to the researcher at the end of the survey. Your email address 
will not be linked to your survey responses. 
 
Ethics Information:  
 
This study has been approved by the Lakehead University Research Ethics Board. If you have 
any questions related to the ethics of the research and would like to speak to someone outside of 








Thank you for your interest and participation, it is greatly appreciated! 
Consent Form for Participants 
 
MY CONSENT:  
 
I have read the information letter and I agree to the following:  
  I have read and understand the information contained in the information letter.  
  I agree to participate.  
  I understand the risks and benefits to the study.  
  That I am a volunteer and can withdraw from the study at any time and may choose not to 
answer any question. (Please note that after you submit your responses they cannot be 
retrieved due to the anonymous nature of the study.)  
  That the data will be securely stored at Lakehead University for a minimum of 5 years 
following completion of the research project.  
  I understand that the research findings will be made available to me upon request. We 
anticipate the study results will be available within 1 year after you complete the study.  
  I will remain anonymous.  
  All of my questions related to the study have been answered.  
 
By consenting to participate, I have not waived any rights to legal recourse in the event of 
research-related harm.  
 
I have read and agree to the above information, I am at least 18 years of age, and by completing 
and submitting this study agree to participate.  
 

















Information Letter [Lakehead University Students] 
Dear Potential Participant, 
 
✆☎ ✁✂ ✄☎✆ ✝☎✞ ✄☎✆✞ ✂✁✟✠✞✠✡✟ ✂✁ ✟☎✠  ✆☎✠ ✝ ✁✁ ☛✂✡ ☞✌✍✠✞✂✠✁✎✠✡ ✏✟✆✑✄✞ ✒✆☎✠ ✝✓✔-E Study). 
This study is being conducted by Shayna Cummings, a MSc Psychological Science student, and 
is supervised by Dr. Dwight Mazmanian, a full-time faculty member in the Department of 
Psychology at Lakehead University. Your participation in this study will help us better 
understand the short-term effects of cannabis use. Before you decide to take part in this study, 
please carefully review the information below to understand what is involved. 
 
What is the purpose of the study? 
 
 ✆☎ ✁✏☛✁✝☞☎ ✝  ✌✆✠☞ ☞✌✏✝✍ ✠☞ ✌✝ ☎✂✂ ✠✟☎ ✁✂☛✌✠✁✠✁✂✟✌☞✄ ☞✆✝☛✌-term effects from cannabis. This study 
will ask questions about your cannabis experiences, but participants do NOT have to use 
cannabis to participate. 
 
How long will the study take to complete? 
 
This survey is not expected to last longer than 1 hour. It is online and hosted on the 
SurveyMonkey platform, so you may complete it at a time and location of your choosing. If you 




If you would like to contact the research team, please send an email to the Student Investigator 
(Shayna Cummings) or the Principal Investigator (Dr. Dwight Mazmanian): 
  slcummin@lakeheadu.ca (Shayna Cummings, HBSc, MSc Psychological Science 
student) 
  dmazmani@lakeheadu.ca (Dwight Mazmanian, PhD, CPsych) 
 
Is the study anonymous? 
 
This study is anonymous. No identifying information will be collected. As no identifying 
information will be collected, no identifying information will be alongside or associated with any 
of the data, analyses, or methods of dissemination. For publication purposes, all survey 
information and responses will be securely stored at Lakehead University for five years. Please 
note, however, that the online survey tool used in the study (SurveyMonkey.com) is hosted by a 
server located in the USA. The US Patriot Act permits U.S. law enforcement officials, for the 
purpose of anti-terrorism investigation, to seek a court order that allows access to the personal 
records of ✂✟✍ ✁☎☛☞✝✟ ✆✠✌✆✝✏✌ ✌✆☎ ✁☎☛☞✝✟✄☞ ✄✟✝✆✂☎✝✞☎✁ ✡✟ ✡✠☎✆ ✝  ✌✆✠☞ ✆☎ ✁✂✟✟✝✌ ✂☎☞✝✂✏✌☎✂✍
guarantee the full anonymity of your data. With your consent to participate in this study, you 
acknowledge this. 
 




Do I have the right to decline to answer any questions? 
 
Participants maintain the right to decline to answer any question(s). Your participation in this 
research is completely voluntary, and if you choose not to participate, you may do so without 
consequence or the need to explain why. You may also discontinue your participation at any time 
without explanation or penalty. Once you submit your data it cannot be withdrawn due to its 
anonymity. 
 
What will the survey be used for? 
 
Participant responses will be used for the thesis of the student investigator, Shayna Cummings. 
The study findings will also be used for research publications and/or presentations at 
conferences. Your identity will remain anonymous throughout these processes as well. 
Researchers who will have access to the data will be limited to Shayna Cummings (MSc 
Psychological Science Student), Casey Oliver (MA Clinical Psychology Student), Erika Puiras 
(MA Clinical Psychology Student), and Dr. Dwight Mazmanian. 
 
How can you benefit from this study? 
 
Potential benefits include participating in research that aims to help in better predicting some 
cannabis short-✌☎☛  ☛☎✂✁✌✠✝✟☞✁  ☞ ✂ ✁✌✆✂✟✄ ✍✝✏✄  ✝☛ ✁✂☛✌✠✁✠✁✂✌✠✟✞ ✠✟ ✌✆✠☞ ☛☎☞☎✂☛✁✆✠ ✍✝u may 
choose to be entered into a draw to win one of five $20 (CDN) electronic gift cards or, if 
you are a student at Lakehead University, you may elect to receive one bonus mark towards an 
eligible psychology course. If you choose to be entered into the draw to win the gift card, you 
will be asked for your email address so you can be contacted if you win. This email will not be 
associated with your responses. If you choose to receive the bonus mark, your instructor at 
Lakehead University must allow the acquisition of bonus marks and you must sign up through 
the Sona System. 
 
What are the risks of participating in this study? 
 
There are no known physical risks associated with participating. However, some of the material 
in the survey asks questions on sensitive subject matter that might result in some minor 
psychological discomfort for some people. If this occurs, please contact the Canadian Mental 
Health Association at 416-646-5557. You may also contact Crisis Services Canada at 1-833-456-
4566. If you are a student at Lakehead University, you may also contact Student Health and 
Wellness at 1-807-343-8361 (Thunder Bay) or at 1-705-330- 4008 ext. 2116 (Orillia). 
 
Can I see the results? 
 
A summary of the research findings may also be available to you once the study is completed. 
Please note that it might take up to 1 year from the time of your participation before the study is 
completed and the findings are available. If you wish to receive a summary of the findings, 
please provide your email address to the researcher at the end of the survey. Your email address 
will not be linked to your survey responses. 
 






This study has been approved by the Lakehead University Research Ethics Board. If you have 
any questions related to the ethics of the research and would like to speak to someone outside of 
the research team, please contact Sue Wright at the Research Ethics Board at 
1-807-343-8283 or research@lakeheadu.ca. 
 
Thank you for your interest and participation, it is greatly appreciated! 
 
Consent Form for Participants 
 
MY CONSENT:  
 
I have read the information letter and I agree to the following:  
  I have read and understand the information contained in the information letter.  
  I agree to participate.  
  I understand the risks and benefits to the study.  
  That I am a volunteer and can withdraw from the study at any time and may choose not to 
answer any question. (Please note that after you submit your responses they cannot be 
retrieved due to the anonymous nature of the study.)  
  That the data will be securely stored at Lakehead University for a minimum of 5 years 
following completion of the research project.  
  I understand that the research findings will be made available to me upon request. We 
anticipate the study results will be available within 1 year after you complete the study.  
  I will remain anonymous.  
  All of my questions related to the study have been answered.  
 
By consenting to participate, I have not waived any rights to legal recourse in the event of 
research-related harm.  
 
I have read and agree to the above information, I am at least 18 years of age, and by completing 
and submitting this study agree to participate.  
 













Debriefing Form [General Public]  
(Please print this page for your information) 
 
Thank you for your participation in this research project on short-term cannabis reactions and 
cannabis experiences. We hope that this study will help provide information about potential 
predictors of short-term cannabis reactions. Information on potential predictors of cannabis 
short-term reactions may better inform and help inexperienced cannabis users, physicians, and 
public health officials. 
 
Information about study results:  
 
A summary of the results can be made available to you by email once the study has been 
completed. If you are interested in receiving these results, please email the Student Investigator, 
Shayna Cummings, at [hhab.laboratory@gmail.com] with the subject head✠✟✞ ✁✡☎☞✏✂✌☞ ✎✏  ✂☛✍
Request for CAN-  ✎✌✏✝✍✄✁✂☎ ✆✠✂✂ ☎ ✂✠✂ ✍✝✏ ✂ ✁✝✁✍ ✝  ✌✆☎ ✡☎☞✏✂✌☞ ✎✏  ✂☛✍ ✝✟✁☎ ✠✌ ✠☞
available. Please note that this may take up to 1 year from the time of your participation.  
 
Electronic Gift Card Draw:  
 
In order to show our appreciation for participating in this research, you may choose to be entered 
into a draw to win one of ten $25 (CAD) electronic gift cards of your choosing (Indigo, Tim 
Hortons, or Walmart). If you enter into the draw to win the electronic gift card, you will be asked 
for your email address in order to be contacted and sent the electronic gift card should you win. 
✡  ✍✝✏ ✝✝ ✟✝✌ ✆✠☞✆ ✌✝ ☎✟✌☎☛ ✌✆☎ ✝☛✂✆✠ ✁✂✠✁✄ ✁☎✁  ✄ ✌✝ ☎✂✠✌ ✌✆☎ ☞✏☛✡☎✍✁  
 
Contact Information:  
 
If you have specific questions about the survey, you may contact the Student Investigator, 
Shayna Cummings, [hhab.laboratory@gmail.com] or the Principal Investigator, Dwight 
Mazmanian, PhD, CPsych, [dmazmani@lakeheadu.ca, 807-343-8257]. 
 
Other Resources:  
 
If completing this survey has raised any issues about mental health concerns that you would like 
to discuss, you may contact the Crisis Services Canada phoneline at 1-833-456-4566.  
 
Thank you for your participation!  
 
Click HERE to enter your email for the electronic gift card draw.  
 
Please note that clicking on the above link will bring you to a new page that is not 
connected to the survey results. Therefore, if you choose to add your email for the 
electronic gift card draw, it will not be associated with your previous responses, which will 
remain anonymous.  





(On a separate page).  
 
Gift Card Draw:  
 
If you would like to be entered into the draw for an electronic gift card, please include your 













































Debriefing Form [Lakehead University Students]  
(Please print this page for your information) 
 
Thank you for your participation in this research project on short-term cannabis reactions. 
We hope that this study will help provide information about potential predictors of short-term 
cannabis reactions. Information on potential predictors of cannabis short-term reactions may 
better inform and help inexperienced cannabis users, physicians, and public health officials. 
 
Information about study results: 
 
A summary of the results can be made available to you by email once the study has been 
completed. If you are interested in receiving these results, please email the Student Investigator, 
✎✆✂✍✟✂ ✂✏  ✠✟✞☞✠ ✂✌  ☞✂✁✏  ✠✟ ✂✂✄☎✆☎✂✝✏✁✁✂✑ ✆✠✌✆ ✌✆☎ ☞✏☎✁☎✁✌ ✆☎✂✝✠✟✞ ✁✡☎☞✏✂✌☞ Summary 
✡☎ ✏☎☞✌✄✁✂☎ ✆✠✂✂ ☎ ✂✠✂ ✍✝✏ ✂ ✁✝✁✍ ✝  ✌✆☎ ✡☎☞✏✂✌☞ ✎✏  ✂☛✍ ✝✟✁☎ ✠✌ ✠☞ ✂✡✂✠✂✂☎le. Please note that 
this may take up to 1 year from the time of your participation. 
 
Bonus Mark or Gift Card Draw: 
 
In order to show our appreciation for participating in this research, you may choose to be entered 
into a draw to win one of five $20 (CDN) electronic gift cards, or you may choose to receive one 
bonus mark towards an eligible Lakehead University psychology course if you are a student at 
Lakehead University. If you choose to be entered into the draw to win the gift card, you will 
be asked for your email address in order to be contacted if you win. Your instructor must 
allow the acquisition of bonus marks to receive one from this study. If you do not wish to 




If you have specific questions about the survey, you may contact the Student Investigator, 
Shayna Cummings, [slcummin@lakeheadu.ca] or the Principle Investigator, Dwight Mazmanian, 




If completing this survey has raised any issues about mental health concerns that you would like 
to discuss, you may contact the Canadian Mental Health Association at 416-646-5557. You may 
also contact Crisis Services Canada at 1-833-456-4566. If you are a student at Lakehead 
University, you may also contact Student Health and Wellness at 1-807-343-8361 (Thunder Bay) 
or at 1-705-330- 4008 ext. 2116 (Orillia). 
 
Thank you for your participation! 
 
Click HERE to enter your email for the gift card draw. 
 




Please note that clicking on the above link will bring you to a new page that is not 
connected to the survey results. Therefore, if you choose to add your email for the gift card 
draw, it will not be associated with your previous responses, which will remain anonymous. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
